https://druglandscape.com/disease/3-beta-hydroxy-delta-5-c27-steroid-dehydrogenase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alk-fusion-gene-positive-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alk-positive-metastatic-nsclc-with-brain-metastases-and-with-or-without-echinoderm-microtubule-associated-protein-like-4-eml4-anaplastic-lymphoma-kinase-alk-fusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alk-positive-metastatic-nsclc-without-brain-metastases 2026-04-19 weekly 0.8 https://druglandscape.com/disease/attr-cm-transthyretin-amyloid-cardiomyopathy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abdominal-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abdominal-actinomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abnormal-uterine-bleeding-due-to-uterine-fibroid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abscess-of-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abscess-of-liver 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abscess-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/absence-seizure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acanthamoeba-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/accidental-poisoning-by-lead-and-its-compounds-and-fumes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/accidental-poisoning-by-methyl-alcohol 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acid-indigestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acne 2026-03-25 weekly 0.8 https://druglandscape.com/disease/acne-vulgaris 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acneiform-eruption 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acquired-factor-viii-deficiency-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acquired-generalized-lipodystrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acquired-hypothyroidism-replacement-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acquired-partial-lipodystrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acquired-thrombocytopenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acromegaly 2026-04-19 weekly 0.8 https://druglandscape.com/disease/actinic-keratosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/actinomycotic-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/activated-pi3k-delta-syndrome-apds- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-juvenile-idiopathic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-plaque-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-psoriatic-arthritis-with-distal-interphalangeal-involvement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-ankylosing-spondylitis-in-adults-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-immunisation-in-infants-children-and-adolescents-6-weeks-to-18-years- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-non-radiographic-axial-spondyloarthritis-with-objective-signs-of-inflammation-in-adults-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-polyarticular-juvenile-idiopathic-arthritis-in-patients-2-years-of-age-and-older-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-psoriatic-arthritis-and-axial-involvement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-psoriatic-arthritis-in-adults-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/active-psoriatic-arthritis-in-pediatric-patients-2-years-of-age-and-older-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-exacerbation-of-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-exacerbation-of-chronic-obstructive-pulmonary-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-sinusitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-solitaire-fr-revascularization-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-trevo-retriever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-trevo-retriever-3d 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-trevo-xp 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-trevo-xp-provue 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-catheter-with-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-mechanical-thrombectomy-xtreem-micro-guidewire-with-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter-and-xtreem-micro-guidewire-and-xtreem-micro-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device-and-a-stentriever-device-and-a-penumbra-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device-and-a-stentriever-device-and-a-trevo-device-and-a-penumbra-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device-and-a-trevo-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-stentriever-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-stentriever-device-and-a-trevo-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-solitaire-fr-revascularization-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-stentriever-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device-and-a-stentriever-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device-and-a-stentriever-device-and-a-trevo-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-solitaire-fr-revascularization-device-and-a-trevo-device-and-a-penumbra-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-stentriever-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-stentriever-device-and-a-penumbra-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-mechanical-thrombectomy-device-and-a-stentriever-device-and-a-trevo-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-solitaire-fr-revascularization-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-solitaire-fr-revascularization-device-and-a-penumbra-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-solitaire-fr-revascularization-device-and-a-trevo-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-stentriever-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-stentriever-device-and-a-penumbra-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-large-vessel-occlusion-and-malignant-cerebral-edema-in-the-posterior-circulation-and-a-baseline-nih-stroke-scale-score-of-10-or-greater-and-a-time-to-treatment-of-4-5-to-6-hours-and-a-stentriever-device-and-a-trevo-device 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-ischemic-stroke-with-a-malignant-cerebral-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-lymphoblastic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-lymphoblastic-leukemia-all-in-pediatric-and-adult-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-lymphoblastic-leukemia-all-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-moraxella-catarrhalis-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myeloid-leukemia 2026-03-25 weekly 0.8 https://druglandscape.com/disease/acute-myeloid-leukemia-aml-in-adult-patients-60-years-or-older-with-at-least-30-bone-marrow-blasts-and-intermediate-2-or-high-risk-cytogenetic-abnormalities-by-the-european-leukemianet-eln-classification 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-pancreatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-st-segment-elevation-myocardial-infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-amebiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-epiglottitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bacterial-skin-and-skin-structure-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-coronary-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-decompensated-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-decompensated-heart-failure-in-patients-receiving-digoxin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-decompensated-heart-failure-in-patients-receiving-diuretics 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-epiglottitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-exacerbation-of-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-exacerbation-of-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-exacerbation-of-chronic-congestive-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-gonococcal-cervicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-gonococcal-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-gonococcal-epididymo-orchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-gonococcal-urethritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-graft-versus-host-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-hypotensive-states-in-adult-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-intermittent-porphyria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-lymphoblastic-leukemia-all-in-adult-patients-who-are-refractory-or-resistant-to-other-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-lymphoid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-lymphoid-leukemia-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-maxillary-sinusitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-migraine-treatment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-monocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-monocytic-monoblastic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myeloblastic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myelogenous-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myeloid-leukemia-aml-in-adult-patients-who-are-refractory-or-resistant-to-other-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myeloid-leukemia-with-fms-like-tyrosine-kinase-3-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myeloid-leukemia-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myelomonocytic-leukemia-fab-m4 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-myocardial-infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-necrotizing-ulcerative-gingivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-otitis-externa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-pain-management 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-postoperative-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-promyelocytic-leukemia-fab-m3 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-pulmonary-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-pyelonephritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-relief-of-angina-pectoris-due-to-coronary-artery-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-treatment-of-chronic-rhinosinusitis-with-and-without-nasal-polyps 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-treatment-of-migraine-attacks-with-or-without-aura-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-treatment-of-migraine-in-pediatric-subjects 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-treatment-of-migraine-with-or-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-treatment-of-migraine-with-or-without-aura-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-uncomplicated-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-uncomplicated-ano-rectal-infections-in-women 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-uncomplicated-urethral-and-cervical-gonorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acyclovir-resistant-mucocutaneous-hsv-in-immunocompromised-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adenocarcinoma-of-pancreas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adenocarcinoma-of-stomach 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adenocarcinoma-of-the-ovary 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adenosine-deaminase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adhesive-capsulitis-of-shoulder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunct-therapy-to-achieve-long-term-asthma-control 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunct-treatment-to-inhibit-renal-drug-excretion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunct-to-fluorouracil-treatment-of-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunct-to-diet-and-exercise-to-improve-glycemic-control-in-adults-with-type-2-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunct-to-incisional-glaucoma-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunctive-therapy-for-partial-onset-seizures-in-patients-1-month-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunctive-therapy-in-the-treatment-of-partial-onset-seizures-in-adults-with-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjunctive-treatment-in-convulsive-disorders 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-renal-cell-carcinoma-rcc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-triple-negative-breast-cancer-tnbc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-chemotherapy-for-women-with-axillary-lymph-node-involvement-following-resection-of-primary-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-therapy-after-tumor-resection-in-adult-patients-with-non-small-cell-lung-cancer-nsclc-whose-tumors-have-epidermal-growth-factor-receptor-egfr-exon-19-deletions-or-exon-21-l858r-mutations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-her2-positive-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-breast-cancer-in-postmenopausal-women-with-hormone-receptor-positive-early-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-colon-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-hormone-receptor-positive-breast-cancer-in-postmenopausal-women-with-disease-recurrence-or-metastasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-hormone-receptor-positive-breast-cancer-in-postmenopausal-women-with-early-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adjuvant-treatment-of-hormone-receptor-positive-invasive-breast-cancer-in-postmenopausal-women-with-disease-recurrence-or-metastasis-after-2-3-years-of-tamoxifen-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/administration-of-corneal-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/administration-of-local-anesthetic-nerve-block 2026-04-19 weekly 0.8 https://druglandscape.com/disease/administration-of-regional-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adolescent-males-with-hypogonadotropic-hypogonadism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adrenal-cortical-hypofunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adrenal-suppression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adrenogenital-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adult-gonococcal-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/adult-growth-hormone-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-brca-mutated-or-hdr-deficient-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-breast-cancer-progression-post-antiestrogen-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-her2positive-gastric-or-gastroesophageal-junction-gej-adenocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-hepatocellular-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-non-squamous-nsclc 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-prostatic-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-ret-fusion-positive-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-ret-fusion-positive-thyroid-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-breast-cancer-in-hormone-receptor-positive-metastatic-breast-cancer-in-patients-with-disease-progression-on-or-after-prior-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-breast-cancer-in-hormone-receptor-positive-metastatic-breast-cancer-in-patients-with-disease-progression-on-or-after-prior-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-breast-cancer-in-postmenopausal-women-with-disease-progression-following-prior-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-melanoma-with-tumour-cell-pd-l1-expression-below-1- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-non-squamous-non-small-cell-lung-cancer-nsclc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-solid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-breast-cancer-in-postmenopausal-women-with-one-or-more-estrogen-receptors-and-or-progesterone-receptors-and-a-her2-negative-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-breast-cancer-in-postmenopausal-women-with-one-or-more-estrogen-receptors-and-or-progesterone-receptors-and-a-her2-positive-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-gastrointestinal-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-negative-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-hormone-receptor-positive-breast-cancer-in-patients-with-disease-progression-on-or-after-endocrine-therapy-and-prior-chemotherapy-in-the-metastatic-setting-and-with-a-pik3ca-mutation-and-with-a-her2-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor-and-with-a-hormone-receptor-positive-tumor-and-with-a-her2-low-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-non-small-cell-lung-cancer-with-a-tumor-harboring-an-egfr-exon-20-insertion-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-non-small-cell-lung-cancer-with-an-activating-egfr-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-solid-tumors-including-ovarian-endometrial-and-breast-neoplasms- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axicabtagene-ciloleucel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axicabtagene-ciloleucel-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-sacituzumab-govitecan 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axicabtagene-ciloleucel-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-sacituzumab-govitecan-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-atezolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axicabtagene-ciloleucel-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-sacituzumab-govitecan-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-atezolizumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-nivolumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axicabtagene-ciloleucel-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-sacituzumab-govitecan-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-atezolizumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-nivolumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-avelumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axicabtagene-ciloleucel-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-sacituzumab-govitecan-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-atezolizumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-nivolumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-avelumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-durvalumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-metastatic-urothelial-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy-and-at-least-one-other-systemic-therapy-and-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-atezolizumab-plus-platinum-containing-chemotherapy-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-axitinib-and-in-patients-who-are-not-eligible-for-durvalumab-plus-tremelimumab-and-in-patients-who-are-not-eligible-for-nivolumab-plus-ipilimumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-lenvatinib-and-in-patients-who-are-not-eligible-for-avelumab-plus-alpelisib-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-axicabtagene-ciloleucel-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-sacituzumab-govitecan-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-atezolizumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-nivolumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-avelumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-durvalumab-and-in-patients-who-are-not-eligible-for-pembrolizumab-plus-sacituzumab-govitecan-plus-cetrelimab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-or-recurrent-cervical-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-ovarian-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-prostate-adenocarcinoma-with-neuroendocrine-differentiation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-renal-cell-carcinoma-rcc-after-failure-of-prior-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-renal-cell-carcinoma-rcc-as-a-first-line-treatment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-solid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-solid-tumors-rp-3467-olaparib-combination- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-solid-tumors-non-small-cell-lung-cancer-melanoma- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-recurrent-anaplasticlymphoma-kinase-alk-positive-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aerobic-gram-negative-bacillary-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aerobic-gram-negative-bacteremia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aerobic-gram-positive-cocci-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/african-trypanosomiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/age-related-macular-degeneration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aggressive-systemic-mastocytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/agitation-associated-with-bipolar-mania 2026-04-19 weekly 0.8 https://druglandscape.com/disease/agitation-associated-with-schizophrenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alcohol-withdrawal-delirium 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alcohol-withdrawal-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alcoholism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aldosteronism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-keratoconjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-reactions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-rhinitis-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-bronchopulmonary-aspergillosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-granulomatosis-angiitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-otitis-externa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-rhinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allergic-urticaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allogeneic-bone-marrow-transplantation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/allogeneic-peripheral-blood-stem-cell-transplant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alopecia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alopecia-areata 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alpha-interferon-refractory-hairy-cell-leukemia-with-active-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alpha-mannosidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alzheimer-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/alzheimers-disease 2026-03-25 weekly 0.8 https://druglandscape.com/disease/amebic-dysentery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amebic-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amebic-liver-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amenorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amenorrhea-secondary-to-ovarian-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/american-mucocutaneous-leishmaniasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amyloid-imaging 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amyloid-polyneuropathy-type-i 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amyloidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amyotrophic-lateral-sclerosis-als- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/amyotrophic-lateral-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaerobic-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaerobic-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaerobic-lung-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaerobic-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaerobic-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaerobic-tubo-ovarian-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaerobic-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/analgesia-in-various-types-of-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaphylaxis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaphylaxis-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaplastic-large-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaplastic-thyroid-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaplastic-large-t-cell-systemic-malignant-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaplastic-lymphoma-kinase-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc-with-brain-metastases 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anaplastic-lymphoma-kinase-positive-anaplastic-large-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ancylostoma-duodenale-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ancylostomiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-due-to-bleeding-uterine-leiomyoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-due-to-and-following-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-due-to-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-due-to-chemotherapy-for-nonmyeloid-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-in-chronic-kidney-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-of-chronic-renal-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-of-prematurity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anemia-of-renal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anesthesia-for-cesarean-section 2026-04-19 weekly 0.8 https://druglandscape.com/disease/angina-pectoris-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/angina-pectoris 2026-04-19 weekly 0.8 https://druglandscape.com/disease/angioedema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/angiographically-documented-cad 2026-04-19 weekly 0.8 https://druglandscape.com/disease/angiomyolipoma-of-kidney 2026-04-19 weekly 0.8 https://druglandscape.com/disease/angle-closure-glaucoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anogenital-warts-external-genital-warts-and-perianal-warts- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anorexia-from-hiv 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anorexia-nervosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anoxia-due-to-high-altitude 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anterior-uveitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anthrax 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anthrax-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anti-neutrophil-cytoplasmic-autoantibody-anca-associated-vasculitis-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/antibiotic-induced-hypoprothrombinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anticholinergic-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anticoagulant-induced-prothrombin-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anticoagulant-induced-prothrombin-deficiency-caused-by-coumarin-derivatives 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anticoagulant-induced-prothrombin-deficiency-caused-by-indanedione-derivatives 2026-04-19 weekly 0.8 https://druglandscape.com/disease/antimicrobial-substance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/antiseptic-preparation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/antiseptic-skin-preparation-for-patient 2026-04-19 weekly 0.8 https://druglandscape.com/disease/antisocial-behavior 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anxiety-associated-with-menopause 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anxiety-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anxiety-due-to-cardiac-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aorta-dextratransposition-with-intact-ventricular-septum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aortography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aphthous-ulcer-of-mouth 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aplastic-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/apnea-in-the-newborn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/appearance-of-upper-facial-lines 2026-04-19 weekly 0.8 https://druglandscape.com/disease/appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/appetite-loss-cachexia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/apprehension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aptyalism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arrhythmias-during-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arterial-embolus-and-thrombosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arteriography-of-cerebral-arteries 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arteriosclerotic-parkinsonism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arteriosclerotic-vascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arthritic-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arthropod-bite-wound 2026-04-19 weekly 0.8 https://druglandscape.com/disease/articular-gout 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ascariasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ascites 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ascorbic-acid-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aspergillosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aspiration-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aspiration-pneumonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/asthma-management 2026-04-19 weekly 0.8 https://druglandscape.com/disease/asthma-night-time-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/asthma-chronic-obstructive-pulmonary-disease-overlap-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/astrocytoma-anaplastic 2026-04-19 weekly 0.8 https://druglandscape.com/disease/asymptomatic-congenital-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/asymptomatic-left-ventricular-systolic-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/at-increased-risk-of-coronary-heart-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/at-risk-of-osteoporotic-fracture 2026-04-19 weekly 0.8 https://druglandscape.com/disease/at-risk-of-venous-thromboembolus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atelectasis-due-to-mucous-obstruction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atherosclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atherosclerotic-cardiovascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atherosclerotic-occlusive-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atonic-seizure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atony-of-uterus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atopic-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atopic-dermatitis-ad- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-and-at-least-one-risk-factor-for-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation-or-flutter-with-a-high-risk-of-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af-and-at-least-one-risk-factor-for-stroke-in-patients-with-a-history-of-stroke-tia-or-non-valvular-af 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrial-flutter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrioventricular-block 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrophic-vaginitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atrophic-vulva 2026-04-19 weekly 0.8 https://druglandscape.com/disease/attention-deficit-hyperactivity-disorder-adhd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/attention-deficit-hyperactivity-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atypical-hemolytic-uremic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/atypical-hemolytic-uremic-syndrome-ahus- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/autism-spectrum-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/autoimmune-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/autoimmune-hemolytic-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/autoimmune-hepatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/autologous-cultured-chondrocytes-for-cartilage-repair 2026-04-19 weekly 0.8 https://druglandscape.com/disease/autologous-stem-cell-transplantation-for-the-treatment-of-hiv 2026-04-19 weekly 0.8 https://druglandscape.com/disease/autologous-hematopoietic-stem-cell-transplantation-for-ewing-s-sarcoma-family-of-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/b-cell-chronic-lymphocytic-leukemia-cll- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/b-cell-precursor-acute-lymphoblastic-leukemia-all- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/b-cell-precursor-acute-lymphoblastic-leukemia-all-that-is-refractory-or-in-second-or-later-relapse 2026-04-19 weekly 0.8 https://druglandscape.com/disease/b-fragilis-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bcg-unresponsive-nonmuscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-cis-with-or-without-papillary-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/braf-mutation-positive-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/brca-mutation-positive-and-her2-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/brca-mutant-breast-cancer-in-combination-with-sapacitabine- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/brca-mutated-g-brca-m-her2-negative-locally-advanced-or-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/brca1-2-mutated-and-hrd-positive-advanced-solid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteremia-caused-by-staphylococcus-aureus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-corneal-ulcer-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-exacerbation-of-acute-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-blepharitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-enteritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-hordeolum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-infection-due-to-klebsiella-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-infection-due-to-serratia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-infection-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-meningitis-due-to-gram-negative-bacteria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-pyelonephritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-urinary-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacterial-vaginosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-brain-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-complicated-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-empyema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-gynecological-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-liver-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-lung-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-postpartum-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-septic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteroides-tubo-ovarian-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bancroft-s-filariasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bardetbiedl-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/barth-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bartonellosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/basal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/basal-cell-carcinoma-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/behcet-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/beh-et-s-disease-affecting-oral-mucosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bejel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/benign-intracranial-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/benign-prostatic-hyperplasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/benzodiazepine-induced-sedation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/benzodiazepine-maintained-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/benzodiazepine-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/berylliosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bilateral-anorchia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bilateral-orchidectomy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bilateral-torsion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biliary-obstruction-with-pruritus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biliary-dyskinesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biliary-tract-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/binge-eating-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-waldenstr-m-macroglobulinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-acute-lymphoblastic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-acute-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-adrenocortical-adenoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-adrenocortical-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-adrenocortical-hyperplasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-anal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-biliary-tract-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-cervical-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-cholangiocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-chronic-lymphocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-chronic-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-cutaneous-squamous-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-diffuse-large-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-endometrial-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-ependymoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-esophageal-squamous-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-fallopian-tube-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-follicular-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-glioblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-glioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-hepatocellular-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-mantle-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-marginal-zone-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-medulloblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-meningioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-multiple-myeloma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-myelodysplastic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-myeloproliferative-neoplasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-neuroblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-ovarian-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-pancreatic-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-paraganglioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-penile-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-pheochromocytoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-primary-central-nervous-system-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-primary-peritoneal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-renal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-soft-tissue-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-synovial-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-thyroid-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-triple-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biomarker-eligible-patients-with-unresectable-or-metastatic-vulvar-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biotin-deficiency-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bipolar-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bipolar-i-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bipolar-affective-disorder-current-episode-depression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bipolar-affective-disorder-current-episode-manic 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bipolar-depression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bipolar-disorder-in-remission 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bladder-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/bladder-muscle-dysfunction-overactive 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blast-crisis-of-chronic-myeloidleukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blastic-phase-chronic-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blastic-plasmacytoid-dendritic-cell-neoplasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blastoid-mantle-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blastomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blepharoconjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blepharospasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blood-pressure-restoration-in-adult-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-marrow-suppression-due-to-folic-acid-antagonism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-marrow-derived-mesenchymal-stem-cells-for-the-treatment-of-graft-versus-host-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-marrow-derived-mesenchymal-stem-cells-for-the-treatment-of-sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-marrow-derived-mesenchymal-stem-cells-for-the-treatment-of-systemic-lupus-erythematosus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-marrow-derived-mesenchymal-stem-cells-for-the-treatment-of-type-1-diabetes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-marrow-derived-mesenchymal-stem-cells-for-the-treatment-of-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-metastases-of-solid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bone-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/boutonneuse-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bowel-and-colon-cleansing-preparation-for-colonoscopy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/branch-retinal-vein-occlusion-with-macular-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breakthrough-pain-in-opioid-tolerant-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breakthrough-cancer-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-neoplasms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-for-palliation-only-in-appropriately-selected-women-and-men-with-metastatic-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-and-her2-negative 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-and-hormone-receptor-positive 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-and-or-prior-endocrine-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-and-or-prior-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-and-or-prior-radiotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-and-or-prior-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-and-or-prior-hormone-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-and-or-prior-targeted-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-and-or-prior-immunotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-and-or-prior-chemotherapy-with-a-taxane 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-and-or-prior-chemotherapy-with-a-platinum-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-and-or-prior-chemotherapy-with-a-microtubule-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-and-or-prior-chemotherapy-with-a-parp-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-and-or-prior-chemotherapy-with-a-cdk4-6-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-and-or-prior-chemotherapy-with-a-mtor-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-and-or-prior-chemotherapy-with-a-her2-targeted-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-prior-chemotherapy-with-a-her2-targeted-therapy-and-or-prior-chemotherapy-with-a-pik3ca-targeted-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-prior-chemotherapy-with-a-her2-targeted-therapy-prior-chemotherapy-with-a-pik3ca-targeted-therapy-and-or-prior-chemotherapy-with-a-hormone-receptor-antagonist 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-prior-chemotherapy-with-a-her2-targeted-therapy-prior-chemotherapy-with-a-pik3ca-targeted-therapy-prior-chemotherapy-with-a-hormone-receptor-antagonist-and-or-prior-chemotherapy-with-a-hormone-receptor-agonist 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-prior-chemotherapy-with-a-her2-targeted-therapy-prior-chemotherapy-with-a-pik3ca-targeted-therapy-prior-chemotherapy-with-a-hormone-receptor-antagonist-prior-chemotherapy-with-a-hormone-receptor-agonist-and-or-prior-chemotherapy-with-a-selective-estrogen-receptor-degrader 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-prior-chemotherapy-with-a-her2-targeted-therapy-prior-chemotherapy-with-a-pik3ca-targeted-therapy-prior-chemotherapy-with-a-hormone-receptor-antagonist-prior-chemotherapy-with-a-hormone-receptor-agonist-prior-chemotherapy-with-a-selective-estrogen-receptor-degrader-and-or-prior-chemotherapy-with-a-selective-estrogen-receptor-modulator 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-prior-chemotherapy-with-a-her2-targeted-therapy-prior-chemotherapy-with-a-pik3ca-targeted-therapy-prior-chemotherapy-with-a-hormone-receptor-antagonist-prior-chemotherapy-with-a-hormone-receptor-agonist-prior-chemotherapy-with-a-selective-estrogen-receptor-degrader-prior-chemotherapy-with-a-selective-estrogen-receptor-modulator-and-or-prior-chemotherapy-with-a-cyclin-dependent-kinase-4-6-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-cdk4-6-inhibitor-resistance-prior-endocrine-therapy-prior-chemotherapy-prior-radiotherapy-prior-surgery-prior-hormone-therapy-prior-targeted-therapy-prior-immunotherapy-prior-chemotherapy-with-a-taxane-prior-chemotherapy-with-a-platinum-agent-prior-chemotherapy-with-a-microtubule-inhibitor-prior-chemotherapy-with-a-parp-inhibitor-prior-chemotherapy-with-a-cdk4-6-inhibitor-prior-chemotherapy-with-a-mtor-inhibitor-prior-chemotherapy-with-a-her2-targeted-therapy-prior-chemotherapy-with-a-pik3ca-targeted-therapy-prior-chemotherapy-with-a-hormone-receptor-antagonist-prior-chemotherapy-with-a-hormone-receptor-agonist-prior-chemotherapy-with-a-selective-estrogen-receptor-degrader-prior-chemotherapy-with-a-selective-estrogen-receptor-modulator-prior-chemotherapy-with-a-cyclin-dependent-kinase-4-6-inhibitor-and-or-prior-chemotherapy-with-a-cdk4-6-inhibitor-and-or-a-pik3ca-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-tp53-mutation-and-or-cdk4-6-inhibitor-resistance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-esr1-mutation-and-or-tp53-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-and-esr1-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-her2-negative-and-esr1-mutation-and-or-tp53-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-cancer-with-a-pik3ca-mutation-hormone-receptor-positive-and-her2-negative 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breastfeeding-mother- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bretovameran-is-not-approved-by-the-fda-it-is-a-research-compound- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/brill-zinsser-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchiectasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchiectasis-mucus-clearance- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchopneumonia-due-to-haemophilus-influenzae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchospasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchospasm-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchospasm-prevention-with-copd 2026-04-19 weekly 0.8 https://druglandscape.com/disease/brucellosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bruxism-teeth-grinding- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bulimia-nervosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bullous-pemphigoid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/burkitt-cell-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/burkitt-s-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/burn-scar-itch 2026-04-19 weekly 0.8 https://druglandscape.com/disease/burn-wound-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/burn-injury 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bursitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bursitis-e-g-olecranon-prepatellar- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bursitis-of-shoulder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ccr5-tropic-drug-resistant-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cd20-positive-diffuse-large-b-cell-non-hodgkin-s-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cd20-positive-follicular-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cd30-positive-peripheral-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chaple-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cmv-retinitis-in-aids-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cmv-retinitis-in-immunocompromised-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/copd-associated-with-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-history-of-severe-allergic-reaction-e-g-anaphylaxis-to-a-previous-dose-of-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose-and-a-tenth-dose-administered-at-least-2-months-after-the-ninth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose-and-a-tenth-dose-administered-at-least-2-months-after-the-ninth-dose-and-an-eleventh-dose-administered-at-least-2-months-after-the-tenth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose-and-a-tenth-dose-administered-at-least-2-months-after-the-ninth-dose-and-an-eleventh-dose-administered-at-least-2-months-after-the-tenth-dose-and-a-twelfth-dose-administered-at-least-2-months-after-the-eleventh-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-12-years-of-age-and-older-with-certain-immunocompromised-individuals 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-history-of-severe-allergic-reaction-e-g-anaphylaxis-to-a-previous-dose-of-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose-and-a-tenth-dose-administered-at-least-2-months-after-the-ninth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose-and-a-tenth-dose-administered-at-least-2-months-after-the-ninth-dose-and-an-eleventh-dose-administered-at-least-2-months-after-the-tenth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-5-years-of-age-and-older-with-certain-immunocompromised-individuals 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-history-of-severe-allergic-reaction-e-g-anaphylaxis-to-a-previous-dose-of-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose-and-a-tenth-dose-administered-at-least-2-months-after-the-ninth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-a-third-dose-administered-at-least-2-months-after-the-second-dose-and-a-fourth-dose-administered-at-least-2-months-after-the-third-dose-and-a-fifth-dose-administered-at-least-2-months-after-the-fourth-dose-and-a-sixth-dose-administered-at-least-2-months-after-the-fifth-dose-and-a-seventh-dose-administered-at-least-2-months-after-the-sixth-dose-and-an-eighth-dose-administered-at-least-2-months-after-the-seventh-dose-and-a-ninth-dose-administered-at-least-2-months-after-the-eighth-dose-and-a-tenth-dose-administered-at-least-2-months-after-the-ninth-dose-and-an-eleventh-dose-administered-at-least-2-months-after-the-tenth-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-prevention-in-individuals-6-months-through-4-years-of-age-with-certain-immunocompromised-individuals 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-treatment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-treatment-in-individuals-12-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age-0-0125-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-intramuscular-injection-0-3-ml-dose-0-3-ml-dose-for-6-11-years-of-age-0-3-ml-dose-for-5-11-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-3-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-2-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-1-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-05-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age-0-025-ml-dose-for-6-months-4-years-of-age-0-0125-ml-dose-for-6-months-4-years-of-age-0-0125-ml-dose-for-6-months-4-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid-19-vaccine-mrna-based-bivalent-xbb-1-5-and-original-strain-subcutaneous-injection- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/covid19-pneumonia-requiring-supplemental-oxygen 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cachexia-due-to-hiv 2026-04-19 weekly 0.8 https://druglandscape.com/disease/calcium-phosphate-renal-calculi 2026-04-19 weekly 0.8 https://druglandscape.com/disease/calcium-renal-calculus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/calculus-in-biliary-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cancer-cachexia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candida-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candida-pleural-space-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidal-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidal-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidal-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidal-vulvovaginitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidemia-and-invasive-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidiasis-of-mouth 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidiasis-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidiasis-of-the-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/candidiasis-of-vagina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoid-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-in-situ-of-adrenal-cortex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-in-situ-of-fallopian-tube 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-of-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-of-cervix 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-of-fallopian-tube 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-of-female-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-of-thyroid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carcinoma-non-small-cell-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiac-decompensation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiac-decompensation-post-cardiac-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiac-function-studies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiac-arrest 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiac-arrhythmia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiac-effects-of-mineralocorticoid-receptor-antagonism-after-preeclampsia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiogenic-shock 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiology 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiomyopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiovascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiovascular-events 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiovascular-morbidity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiovascular-mortality 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiovascular-risk 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardioversion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardioversion-of-atrial-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardioversion-of-atrial-flutter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/carnitine-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/castleman-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/castration-resistant-prostate-cancer-bone-metastases 2026-04-19 weekly 0.8 https://druglandscape.com/disease/castration-resistant-prostate-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/catabolic-process 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cataplexy-and-narcolepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cataract-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/catch-up-vaccination-for-adults-19-through-26-years-of-age-who-have-not-previously-completed-the-series 2026-04-19 weekly 0.8 https://druglandscape.com/disease/catch-up-vaccination-for-adults-27-years-of-age-and-older-who-have-not-previously-completed-the-series 2026-04-19 weekly 0.8 https://druglandscape.com/disease/catch-up-vaccination-for-individuals-13-through-18-years-of-age-who-have-not-previously-completed-the-series 2026-04-19 weekly 0.8 https://druglandscape.com/disease/celiac-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/central-retinal-vein-occlusion-with-macular-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cerebral-cysticercosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cerebral-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cerebral-embolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cerebral-ischemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cerebrovascular-occlusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cerebrovascular-accident 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cerebrovascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cervical-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cervical-dystonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cervical-ripening-procedure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cervicofacial-actinomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cesarean-section-infection-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chancroid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chemotherapy-induced-hyperuricemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chemotherapy-induced-hypogonadism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chemotherapy-induced-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chemotherapy-induced-neutropenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chemotherapy-naive-metastatic-castration-resistant-prostate-cancer-mcrpc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chickenpox-varicella- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/childhood-absence-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chlamydia-cervicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chlamydia-pneumoniae-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chlamydia-trachomatis-infection-of-genital-structure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chlamydial-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chlamydial-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chlamydial-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chlamydial-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chloasma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chloroquine-resistant-plasmodium-falciparum-malaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chloroquine-resistant-plasmodium-falciparum-malaria-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholangiogram 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholangitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholecystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholelithiasis-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholera 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholestanol-storage-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholestatic-pruritus-in-patients-with-alagille-syndrome-algs- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cholinesterase-inhibitors-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-chondroid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-dedifferentiated 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-enchondroid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-myxoid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-not-otherwise-specified 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-papillary 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-megakaryoblastic-differentiation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-rhabdoid-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chordoma-squamous-with-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-undifferentiated-features-and-spindle-cell-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chorioretinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/choroidal-retinal-neovascularization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/choroiditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chromoblastomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-bacterial-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-and-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-with-aura-and-migraine-without-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-with-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-with-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-cluster-headache-without-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-enterococcus-faecalis-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-escherichia-coli-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-familial-amyloid-polyneuropathy-hattr-in-adults-with-a-family-history-of-the-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-fatigue-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-heart-failure-following-myocardial-infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-with-aura-and-migraine-without-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-with-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-with-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hemicrania-continua-without-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hepatitis-c-genotypes-1-6- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-iron-overload 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-lymphocytic-leukemia 2026-03-25 weekly 0.8 https://druglandscape.com/disease/chronic-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-with-aura-and-migraine-without-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-with-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-with-aura-and-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-with-aura-and-migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-with-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-with-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-migraine-without-aura-and-migraine-without-aura-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-musculoskeletal-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-myelocytic-leukemia-accelerated-phase 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-myeloid-leukemia-cml-in-adult-patients-with-philadelphia-chromosome-positive-ph-disease-who-are-refractory-or-resistant-to-at-least-one-prior-tyrosine-kinase-inhibitor-tki-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-non-allergic-rhinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/copd 2026-03-25 weekly 0.8 https://druglandscape.com/disease/chronic-obstructive-pulmonary-disease-with-bronchospasms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-occlusive-peripheral-arterial-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-pain-with-opioid-tolerance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-stable-angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-staphylococcus-epidermidis-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-antibioticrefractory-ileal-pouchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-constipation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-eosinophilic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-gastritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-gouty-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-graft-versus-host-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-graft-versus-host-disease-chronic-gvhd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hepatitis-c 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hepatitis-c-japanese-population- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hepatitis-c-genotype-1- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hepatitis-c-treatment-na-ve-and-treatment-experienced- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-hepatitis-c-virus-infection-genotypes-1-6- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-idiopathic-constipation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-idiopathic-neutropenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-idiopathic-thrombocytopenic-purpura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-idiopathic-urticaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-infantile-neurological-cutaneous-and-articular-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-infection-caused-by-hepatitis-d-virus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-intestinal-amebiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-kidney-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-kidney-disease-ckd-associated-with-type-2-diabetes-t2d- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-kidney-disease-at-increased-risk-of-cardiovascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-low-back-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-lymphocytic-leukemia-cll-in-adult-patients-who-are-refractory-or-resistant-to-other-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-lymphocyticleukemia-small-lymphocytic-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-lymphoid-leukemia-with-vitamin-d3-substitution 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-lymphoid-leukemia-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-myeloid-leukemia-cml-in-adult-patients-who-are-refractory-or-resistant-to-other-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-myelomonocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-non-neuropathic-gaucher-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-obstructive-lung-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-phase-chronic-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-schizophrenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-sialorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-sinusitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-stable-angina-classic-effort-associated-angina- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-thromboembolic-pulmonary-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-tubotympanic-suppurative-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-type-b-viral-hepatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-ulcerative-proctitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-ulcerative-rectosigmoiditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-viral-hepatitis-b-with-hepatitis-d 2026-04-19 weekly 0.8 https://druglandscape.com/disease/citrobacter-complicated-uti 2026-04-19 weekly 0.8 https://druglandscape.com/disease/citrobacter-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/citrobacter-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/citrobacter-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/citrobacter-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/citrobacter-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/citrullinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/classical-hodgkin-lymphoma-chl- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/classical-hodgkin-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/classical-phenylketonuria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clonorchiasis-due-to-c-sinensis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-liver-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-perfringens-empyema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-tubo-ovarian-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-difficile-diarrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clostridium-difficile-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cluster-headache-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cluster-headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cluster-headache-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/coarctation-of-aorta 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cobalamin-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cocaine-use-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/coccidioidomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cold-sores-herpes-labialis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cold-autoimmune-hemolytic-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/colonoscopy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/colorectal-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/colorectal-perioperative-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/colorectal-surgery-infection-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/common-cold 2026-04-19 weekly 0.8 https://druglandscape.com/disease/community-acquired-bacterial-pneumonia-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/community-acquired-pneumonia-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/community-acquired-pneumonia-in-hospitalized-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/community-acquired-bacterial-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/community-acquired-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/comparing-sesame-oil-nitroglycerin-ointment-and-aloe-vera-gel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/compensated-cirrhosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complement-3-glomerulopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complex-dyslipidemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-bacterial-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-bacteroides-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-e-coli-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-genitourinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-klebsiella-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-proteus-uti 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-e-coli-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-enterococcus-faecalis-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-proteus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-pseudomonas-aeruginosa-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-staphylococcus-aureus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-streptococcus-agalactiae-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-streptococcus-pyogenes-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-skin-and-skin-structure-streptococcus-dysgalactiae-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-streptococcus-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-uti-with-pseudomonas-aeruginosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-urinary-tract-infection-due-to-acinetobacter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-ciai-caused-by-certain-susceptible-bacteria- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-urinary-tract-infections-cuti-including-pyelonephritis-caused-by-certain-susceptible-bacteria- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/computed-tomography-of-entire-head 2026-04-19 weekly 0.8 https://druglandscape.com/disease/condition-listed-above-or-as-directed-by-the-physician 2026-04-19 weekly 0.8 https://druglandscape.com/disease/conditioning-treatment-prior-to-allogeneic-haematopoietic-stem-cell-transplant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/conduction-disorders 2026-04-19 weekly 0.8 https://druglandscape.com/disease/condyloma-acuminatum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-heart-defect-requiring-open-patent-ductus-arteriosus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-adrenal-hyperplasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-atresia-of-the-pulmonary-valve 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-atresia-of-tricuspid-valve 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-cytomegalovirus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-generalized-lipodystrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-hemolytic-uremic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-hyperammonemia-type-i 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-hyperinsulinism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-hypoplastic-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-hypothyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-hypothyroidism-replacement-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-myotonia-autosomal-dominant-form 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-neutropenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congenital-toxoplasmosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congestive-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/conscious-sedation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/constipation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/contact-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/contact-dermatitis-due-to-poison-oak 2026-04-19 weekly 0.8 https://druglandscape.com/disease/continuation-therapy-for-acute-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/continuation-therapy-for-chronic-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/contraception 2026-04-19 weekly 0.8 https://druglandscape.com/disease/contrast-media-induced-nephrotoxicity-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/control-of-ventricular-rate-at-rest-in-patients-with-chronic-atrial-flutter-and-or-atrial-fibrillation-in-association-with-digitalis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/control-of-ventricular-rate-during-stress-in-patients-with-chronic-atrial-flutter-and-or-atrial-fibrillation-in-association-with-digitalis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/controlled-hypotension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/controlled-ovarian-stimulation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/conversion-of-atrial-fibrillation-flutter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/corneal-abrasion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/corneal-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/coronary-artery-disease-cad- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/coronary-artery-calcification-in-hemodialysis-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/corpus-luteum-insufficiency-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cosyntropin-preparation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cough 2026-04-19 weekly 0.8 https://druglandscape.com/disease/critical-illness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/crohn-s-disease-in-remission 2026-04-19 weekly 0.8 https://druglandscape.com/disease/crohns-disease 2026-03-25 weekly 0.8 https://druglandscape.com/disease/crow-fukase-poems-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cryopyrin-associated-periodic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cryptococcal-meningitis-in-hiv 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cryptococcal-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cryptococcal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cryptococcosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cryptogenic-ischemic-stroke-with-patent-foramen-ovale-pfo- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cryptorchidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-fibroblasts-for-the-treatment-of-aesthetic-facial-rejuvenation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-fibroblasts-for-the-treatment-of-facial-wrinkles 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-fibroblasts-for-the-treatment-of-photoaging 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-keratinocytes-for-the-treatment-of-severe-burns 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-keratinocytes-for-the-treatment-of-severe-wounds 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-melanocytes-for-the-treatment-of-vitiligo 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-osteoblasts-for-the-treatment-of-osteogenesis-imperfecta 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-osteoblasts-for-the-treatment-of-spinal-fusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-osteoblasts-for-the-treatment-of-spinal-osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-osteoblasts-for-the-treatment-of-traumatic-bone-fractures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-osteoblasts-for-the-treatment-of-vertebral-compression-fractures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-stromal-vascular-fraction-for-the-treatment-of-aesthetic-facial-rejuvenation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-stromal-vascular-fraction-for-the-treatment-of-facial-wrinkles 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-stromal-vascular-fraction-for-the-treatment-of-photoaging 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-severe-burns 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-severe-wounds 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-vitiligo 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-diabetic-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-trauma-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-vascular-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-venous-ulcer-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-diabetic-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-trauma-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-vascular-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-venous-ulcer-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-diabetic-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-trauma-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-vascular-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-venous-ulcer-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-diabetic-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-trauma-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-vascular-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-venous-ulcer-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-diabetic-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-trauma-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-vascular-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-venous-ulcer-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-diabetic-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-trauma-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-vascular-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-venous-ulcer-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-diabetic-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cultured-autologous-tissue-engineered-skin-substitute-for-the-treatment-of-wound-healing-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-wound-care-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/curare-overdose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cushing-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cutaneous-lupus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cutaneous-tcell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cutaneous-anthrax 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cutaneous-larva-migrans 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cutaneous-leishmaniasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cyclical-neutropenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cyclitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cycloplegia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystic-aponeurosis-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystic-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystic-fibrosis-general- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystic-fibrosis-with-burkholderia-spp-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystic-fibrosis-of-the-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystine-renal-calculi 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystinosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystinuria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cytokine-release-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cytokine-release-syndrome-induced-by-tumor-specific-t-cell-infusion-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cytomegaloviral-retinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cytomegalovirus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dlbcl-arising-from-follicular-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dlbcl-arising-from-low-grade-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dacryocystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dapsone-resistant-leprosy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/data-not-available 2026-04-19 weekly 0.8 https://druglandscape.com/disease/debridement-of-wound-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/decompensated-cardiac-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/decompensated-chronic-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/decompensated-cirrhosis-of-liver 2026-04-19 weekly 0.8 https://druglandscape.com/disease/decreased-respiratory-function 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deep-vein-thrombosis-with-pulmonary-embolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deep-mycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deep-vein-thrombosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deep-venous-thrombosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deficiency-of-aromatic-l-amino-acid-decarboxylase 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deficiency-of-carbamylphosphate-synthetase-cps- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deficiency-of-mevalonate-kinase 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deficiency-of-testosterone-biosynthesis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/deficiency-or-absence-of-endogenous-testosterone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/degeneration-of-intervertebral-disc 2026-04-19 weekly 0.8 https://druglandscape.com/disease/delayed-puberty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/delta-4-3-oxosteroid-5-beta-reductase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dementia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dementia-associated-with-parkinson-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/demodex-blepharitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dental-plaque 2026-04-19 weekly 0.8 https://druglandscape.com/disease/depression-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/depressive-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dermatitis-herpetiformis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dermatofibrosarcoma-protuberans 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dermatographic-urticaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dermatomyositis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dermatophytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dermatosis-of-scalp 2026-04-19 weekly 0.8 https://druglandscape.com/disease/detect-and-visualize-lesions-with-abnormal-vascularity-with-mri 2026-04-19 weekly 0.8 https://druglandscape.com/disease/detection-of-hypothalamic-or-pituitary-tumors-or-anatomical-changes-associated-with-increased-intracranial-pressure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/development-of-multiple-follicles-and-pregnancy-in-ovulatory-women-as-part-of-an-assisted-reproductive-technology-art-cycle 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetes-mellitus-type-1 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetes-mellitus-type-2 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetes-mellitus-type-2-at-increased-risk-of-cardiovascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-foot-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-foot-infection-due-to-gram-positive-bacteria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-dyslipidemia-associated-with-type-2-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-gastroparesis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-nephropathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-neuropathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-peripheral-neuropathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-renal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-retinopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-hypercortisolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-allergic-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-amyloid-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-bacterial-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-cardiovascular-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-dermatological-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-eye-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-fungal-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-gastrointestinal-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-genitourinary-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-immunological-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-infectious-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-musculoskeletal-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-neurodegenerative-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-neurodevelopmental-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-neuroinfectious-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-neuroinflammatory-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-neurological-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-neuromuscular-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-parasitic-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-poisoning 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-prion-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-psychiatric-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-respiratory-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-certain-types-of-viral-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-congenital-and-acquired-renal-abnormalities 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-cyanide-poisoning 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-methemoglobinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnosis-of-renal-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-cushing-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-gonadotropin-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-growth-hormone-secretion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-myasthenia-gravis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-pancreas-function 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-pancreatic-islet-cell-adenoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-primary-aldosteronism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-secondary-adrenocortical-insufficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-test-for-thyroid-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diagnostic-aid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diarrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diarrhea-secondary-to-inflammatory-bowel-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diarrhea-due-to-e-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diarrhea-from-pancreatic-vipoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/difficulty-passing-urine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diffuse-lewy-body-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diffuse-proliferative-lupus-nephritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diffuse-large-b-cell-lymphoma-refractory 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diffuse-non-hodgkin-s-lymphoma-large-cell 2026-04-19 weekly 0.8 https://druglandscape.com/disease/digestive-system-radiography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/digitalis-toxicity-by-ekg 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dilated-pupil 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diphtheria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diphtheroid-prosthetic-heart-valve-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/direct-acting-anticoagulant-adverse-reaction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/discoid-lupus-erythematosus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/discoloration-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disease-caused-by-severe-acute-respiratory-syndrome-coronavirus-2 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disease-caused-by-rickettsiae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-due-to-type-2-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-biliary-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-blood-vessel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-cardiovascular-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-electrolytes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-eye 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-keratinization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-lumbar-disc 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-musculoskeletal-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorder-of-the-urea-cycle-metabolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disorders-of-initiating-and-maintaining-sleep 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disruptive-behavior-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disseminated-gonococcal-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disseminated-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disseminated-intravascular-coagulation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disseminated-sporotrichosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diverticulitis-of-gastrointestinal-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/documented-ventricular-arrhythmias 2026-04-19 weekly 0.8 https://druglandscape.com/disease/doxorubicin-induced-cardiomyopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dravet-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/drug-resistant-tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/drug-induced-pyridoxine-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/drug-induced-coagulation-inhibitor-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/drug-induced-hypoprothrombinemia-caused-by-salicylates 2026-04-19 weekly 0.8 https://druglandscape.com/disease/drug-induced-mucositis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/drug-induced-osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dry-eye-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/duchenne-muscular-dystrophy-early-stage- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/duchenne-muscular-dystrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/duchenne-muscular-dystrophy-dmd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/duodenal-ulcer-due-to-h-pylori 2026-04-19 weekly 0.8 https://druglandscape.com/disease/duodenal-ulcer-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dupuytren-s-disease-of-finger-with-contracture 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dysentery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dysfunctional-uterine-bleeding 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dyslipidemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dysmenorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dyspareunia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dyspepsia-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dyspnea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dysrhythmia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dysuria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-cervicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-complicated-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-genitourinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-gynecological-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-lung-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-postpartum-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-pyelonephritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-septic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/e-coli-septic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/egfr-mutation-positive-inoperable-or-reccrent-nsclc 2026-04-19 weekly 0.8 https://druglandscape.com/disease/egfr-mutation-positive-unresectable-or-recurrent-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer-with-disease-progression-following-at-least-one-line-of-endocrine-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/esr1-mutated-advanced-or-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/early-breast-cancer-hormone-receptor-positive-and-postmenopausal 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eaton-lambert-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ebola-virus-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ebstein-s-anomaly-of-tricuspid-valve 2026-04-19 weekly 0.8 https://druglandscape.com/disease/echinococcus-granulosus-infection-of-the-peritoneum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/echinococcus-granulosus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/echinococcus-granulosus-infection-of-liver 2026-04-19 weekly 0.8 https://druglandscape.com/disease/echinococcus-granulosus-infection-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/echocardiography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ecthyma-gangrenosum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eczema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-associated-with-congestive-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-associated-with-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-associated-with-hepatic-cirrhosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-associated-with-hepatic-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-associated-with-renal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-due-to-hepatic-cirrhosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-due-to-nephrotic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-due-to-corticosteroid-and-estrogen-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-due-to-renal-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-in-cirrhotic-patients-unresponsive-to-fluid-and-sodium-restriction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-in-nephrotic-syndrome-with-inadequate-response-to-other-treatments 2026-04-19 weekly 0.8 https://druglandscape.com/disease/edema-of-larynx 2026-04-19 weekly 0.8 https://druglandscape.com/disease/effect-of-topically-applied-milrinone-or-nitroglycerin-on-internal-mammary-artery-free-flow 2026-04-19 weekly 0.8 https://druglandscape.com/disease/efficacy-and-safety-of-olmesartan-associated-with-chlorthalidone-in-essential-arterial-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/electrocardiogram-abnormalities 2026-04-19 weekly 0.8 https://druglandscape.com/disease/embolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/empyema-of-pleura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/encephalitis-caused-by-human-herpesvirus-6-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/encephalitis-due-to-herpesvirus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/encephalitis-due-to-toxoplasmosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/end-stage-kidney-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endometrial-ablation-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endometrial-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/endometrial-hyperplasia-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endometrial-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endometrial-carcinoma-progressing-after-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endometriosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endoscopic-photodynamic-ablation-adjunct-for-cancer-or-high-grade-dysplasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endoscopy-of-female-reproductive-organs-with-hysterosalpingography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/energy-levels-in-healthy-volunteers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enhancement-of-an-antitumor-effect-of-dinutuximab-for-neuroblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enhancing-wound-perfusion-in-high-risk-lower-extremity-orthopaedic-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enteric-campylobacteriosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-cloacae-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacter-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobacterjoint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterobiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-complicated-uti 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-genitourinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-postpartum-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-septic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterococcus-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/enterocolitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eosinophilic-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eosinophilic-esophagitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epicondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epicondylitis-e-g-tennis-elbow- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epidermolysis-bullosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epilepsy-characterized-by-intractable-complex-partial-seizures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epilepsy-having-focal-onset-seizures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epithelial-tumor-of-ovary 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epithelioid-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erdheim-chester-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erosive-esophagitis-in-pediatric-patients-1-to-11-years-old 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erosive-esophagitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eruption-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erysipelas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erysipeloid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythema-multiforme 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythema-nodosum-leprosum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythrasma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythroblastic-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythroderma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythrodermic-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythroleukemia-fab-m6 2026-04-19 weekly 0.8 https://druglandscape.com/disease/erythropoietic-protoporphyria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/escherichia-coli-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/escherichia-coli-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/esophageal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/esophageal-squamous-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/esotropia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/essential-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/essential-thrombocythemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/essential-thrombocythemia-et-in-adult-patients-who-are-refractory-or-resistant-to-other-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/essential-tremor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/estrogen-receptor-positive-advanced-or-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ethylene-glycol-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eubacterium-liver-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eubacterium-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/eustachian-tube-congestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/evaluating-the-effects-of-nitroglycerin-on-heart-function-and-urinary-output-in-patients-with-acute-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/evaluation-of-vascular-and-tissue-blood-flow 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ewing-s-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exacerbation-of-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exacerbation-of-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/excess-subcutaneous-fat 2026-04-19 weekly 0.8 https://druglandscape.com/disease/excessive-salivation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exclusion-of-other-causes-of-sexual-precocity-such-as-congenital-adrenal-hyperplasia-testotoxicosis-testicular-tumors-and-or-other-autonomous-feminizing-or-masculinizing-disorders 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exercise-induced-bronchospasm-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exfoliative-erythroderma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exposure-to-americium-radiation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exposure-to-curium-radiation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exposure-to-plutonium-radiation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/extended-treatment-of-symptomatic-venous-thromboembolism-to-reduce-recurrence-in-adult-patients-with-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/extensive-stage-primary-small-cell-carcinoma-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/extrapyramidal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/extrapyramidal-sign 2026-04-19 weekly 0.8 https://druglandscape.com/disease/extravasation-injury-from-anthracycline-injection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/extrinsic-allergic-alveolitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/exudative-age-related-macular-degeneration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fgfr1-fusion-genepositive-myeloid-lymphoid-neoplasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fabry-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/facial-fine-wrinkling 2026-04-19 weekly 0.8 https://druglandscape.com/disease/facial-hyperpigmentation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/factor-ii-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/factor-ix-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/factor-vii-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/factor-viii-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/factor-viii-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/falciparum-malaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-mediterranean-fever-fmf- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-mediterranean-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-hypercholesterolemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-hypercholesterolemia-heterozygous 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-hypercholesterolemia-homozygous 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-lipoprotein-lipase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-type-3-hyperlipoproteinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-x-linked-hypophosphatemic-vitamin-d-refractory-rickets 2026-04-19 weekly 0.8 https://druglandscape.com/disease/febrile-neutropenia-caused-by-myelosuppressive-anti-cancer-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/feeling-agitated 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-facial-hirsutism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-urethral-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-castration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-genital-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-hypogonadism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-hypogonadism-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-infertility 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-pelvic-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/female-stress-incontinence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fibrocystic-breast-changes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fibromyalgia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fibrosis-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fine-wrinkling 2026-04-19 weekly 0.8 https://druglandscape.com/disease/first-line-treatment-of-adult-patients-with-locally-advanced-or-metastatic-nsclc-whose-tumors-have-egfr-exon-19-deletions-or-exon-21-l858r-mutations-in-combination-with-pemetrexed-and-platinum-based-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/first-line-treatment-of-adult-patients-with-metastatic-nsclc-whose-tumors-have-egfr-exon-19-deletions-or-exon-21-l858r-mutations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/first-line-treatment-of-metastatic-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/first-line-treatment-of-patients-with-squamous-cell-carcinoma-of-the-head-and-neck-scchn-in-combination-with-5-fluorouracil-and-radiation-therapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fluid-retention-in-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fluorescein-staining-of-eye 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fluorescent-stain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/folic-acid-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/follicular-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/follicular-non-hodgkin-s-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/follicular-thyroid-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/folliculitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fracture-of-tibia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/friedreich-s-ataxia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/frozen-shoulder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/functional-bowel-irritable-bowel-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-blepharitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-infection-due-to-fusarium-solani 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-infection-due-to-scedosporium-apiospermum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-infection-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fungal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/furunculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fusarium-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fusobacterium-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fusobacterium-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fusospirochetal-pharyngitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gangrenous-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gardnerella-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gardnerella-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gardnerella-postpartum-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gardnerella-septic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gardnerella-vaginalis-bacterial-vaginosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gas-gangrene-caused-by-clostridium-perfringens 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastric-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastric-hypersecretory-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastric-or-gastroesophageal-junction-adenocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastric-spasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastric-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastro-esophageal-reflux-disease-with-esophagitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastroenteritis-due-to-salmonella 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastroesophageal-reflux-disease-gerd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastroesophageal-reflux-disease-gerd-in-pediatric-patients-1-to-11-years-old 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastroesophageal-reflux-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastrointestinal-radiography-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastrointestinal-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastrointestinal-anthrax 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastrointestinal-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastrointestinal-infection-caused-by-klebsiella-aerogenes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastrointestinal-stromal-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gastroparesis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/general-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/generalized-anxiety-disorder-gad- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/generalized-anxiety-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/generalized-myasthenia-gravis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/generalized-pustular-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/genital-herpes-initial-episode- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/genital-herpes-recurrent-episodes- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/genital-herpes-simplex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/genitourinary-tract-infection-due-to-proteus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/genitourinary-tract-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/geographic-atrophy-secondary-to-age-related-macular-degeneration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/germline-brca-mutated-her2-negative-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gestational-trophoblastic-neoplasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/giant-cell-arteritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/giant-cell-arteritis-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/giant-papillary-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/giardiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gilles-de-la-tourette-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gingival-disorders 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gingivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gingivitis-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gingivostomatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glabellar-lines 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glanzmann-s-thrombasthenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glaucoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glioblastoma 2026-03-25 weekly 0.8 https://druglandscape.com/disease/glioblastoma-multiforme 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glioblastoma-multiforme-of-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glioma-malignant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glossopharyngeal-neuralgia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glucocorticoid-induced-osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/glucosylceramide-beta-glucosidase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/goiter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gold-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gonococcal-conjunctivitis-neonatorum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gonococcal-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gonococcal-infection-of-joint 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gonococcal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gonorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gonorrhea-of-pharynx 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gonorrhea-of-rectum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gorham-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gout 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gout-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gouty-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/grade-2-astrocytoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/grade-2-oligodendroglioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gram-negative-aerobic-bacillary-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/gram-negative-bacterial-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/granuloma-annulare 2026-04-19 weekly 0.8 https://druglandscape.com/disease/granuloma-inguinale 2026-04-19 weekly 0.8 https://druglandscape.com/disease/granulomatosis-infantiseptica 2026-04-19 weekly 0.8 https://druglandscape.com/disease/granulomatosis-with-polyangiitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/graves-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/greasy-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/group-b-streptococcus-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/growth-failure-due-to-inadequate-secretion-of-endogenous-growth-hormone-gh- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/growth-hormone-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/growth-retardation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/h-influenzae-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/her2-negative-advanced-or-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/her2-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/her2-positive-carcinoma-of-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/her2-positive-colon-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/her2-positive-rectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/her2-positive-salivary-gland-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/her2negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv-1-infection-in-combination-with-other-antiretroviral-agents-in-pediatric-patients-4-weeks-of-age-and-older-and-weighing-at-least-3-kg-in-the-absence-of-antiretroviral-treatment-failure-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater-and-with-no-prior-antiretroviral-therapy-and-with-viral-load-100-000-copies-ml-or-less-and-with-cd4-percentage-25-or-greater 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiv 2026-03-25 weekly 0.8 https://druglandscape.com/disease/hnscc-pd-l1- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hnscc-pd-l1-post-platinum- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hnscc-first-line- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hnscc-post-platinum- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hr-her2-metastatic-breast-cancer-ovarian-cancer-fallopian-tube-cancer-primary-peritoneal-cancer-triple-negative-breast-cancer-male-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer-mcrpc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemangioma-with-a-risk-of-permanent-scars-or-disfigurement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-influenzae-acute-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-influenzae-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-influenzae-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-influenzae-lung-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-influenzae-pharyngitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-influenzae-type-b-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-parainfluenzae-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-parainfluenzae-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-parainfluenzae-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-septic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/haemophilus-influenzae-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hairy-cell-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hairy-cell-leukemia-patients-with-clinically-significant-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hairy-cell-leukemia-patients-with-disease-related-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hairy-cell-leukemia-patients-with-neutropenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hairy-cell-leukemia-patients-with-thrombocytopenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hand-wash-for-healthcare-personnel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hashimoto-thyroiditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hb-ss-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/head-and-neck-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/head-and-neck-squamous-cell-carcinoma-hnscc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/head-and-neck-squamous-cell-carcinoma-hnscc-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/head-and-neck-squamous-cell-carcinoma-hnscc-in-adults-in-combination-with-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/head-and-neck-squamous-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/headache-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/healthspan-improvement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/healthy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heart-block 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heart-failure-with-overactive-bladder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heartburn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heartburn-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemangioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemicrania-continua 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemicrania-continua-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemodynamically-unstable-ventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemoglobin-ss-disease-with-crisis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemolysis-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-a 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-a-or-b 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-a-with-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-b 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemorrhage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemorrhagic-disease-of-the-newborn-due-to-vitamin-k-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemorrhaging-in-hemophilia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemorrhoids 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heparin-overdose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatic-coma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatic-encephalopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatic-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatic-porphyria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-booster- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-infant- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-newborn- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-travel- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-and-hepatitis-b 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-and-typhoid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-a-and-typhoid-oral- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-booster- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-infant- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-newborn- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-recurrence- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-b-travel- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatitis-c 2026-03-25 weekly 0.8 https://druglandscape.com/disease/hepatocellular-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatorenal-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hereditary-angioedema-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hereditary-c1-esterase-inhibitor-deficiency-deficient-factor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hereditary-angioneurotic-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hereditary-factor-ix-deficiency-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hereditary-factor-viii-deficiency-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hereditary-factor-xiii-a-subunit-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-zoster-shingles- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-labialis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-simplex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-simplex-dendritic-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-simplex-infection-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-simplex-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-zoster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-zoster-keratoconjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heterotopic-ossification 2026-04-19 weekly 0.8 https://druglandscape.com/disease/heterozygous-familial-hypercholesterolemia-hefh- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiatal-hernia-with-reflux-esophagitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/high-grade-dysplasia-associated-with-barrett-s-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/high-blood-pressure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/high-grade-squamous-intraepithelial-neoplasia-of-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/high-risk-smoldering-multiple-myeloma-as-monotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/high-grade-serous-ovarian-cancer-idetrexed-olaparib- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hip-replacement-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/histiocytic-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/histoplasmosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/history-of-myocardial-infarction-due-to-atherothrombotic-coronary-artery-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hodgkin-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hodgkin-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/homocystinuria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/homogentisate-1-2dioxygenase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/homozygous-familial-hypercholesterolemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/horizontal-forehead-lines 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-receptor-positive-malignant-neoplasm-of-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-receptor-pozitive-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-receptor-positive-hr-human-epidermal-growth-factor-receptor-2-negative-her2-negative-advanced-or-metastatic-breast-cancer-in-combination-with-fulvestrant-in-women-with-disease-progression-following-endocrine-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-receptor-positive-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-receptor-positive-her2-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-her2-negative-advanced-or-metastatic-breast-cancer-in-combination-with-an-aromatase-inhibitor-as-initial-endocrine-based-therapy-in-postmenopausal-women-with-estrogen-receptor-positive-er-her2-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-her2-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-refractory-prostate-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-replacement-cycle-in-embryo-transfer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hospital-acquired-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia-habp-vabp-caused-by-certain-susceptible-bacteria- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hospital-acquired-bacterial-pneumonia-caused-by-acinetobacter-baumannii-calcoaceticus-complex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hot-flashes-associated-with-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-african-trypanosomiasis-hat-due-to-trypanosoma-brucei-gambiense 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-papillomavirus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-epidermal-growth-factor-2-negative-carcinoma-of-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-epidermal-growth-factor-2-positive-gastric-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-immunodeficiency-virus-i-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-immunodeficiency-virus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-papillomavirus-hpv- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-papillomavirus-hpv-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-papillomavirus-hpv-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-papillomavirus-hpv-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-papillomavirus-hpv-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-papillomavirus-hpv-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/humoral-hypercalcemia-of-malignancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/huntington-s-chorea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hurthle-cell-carcinoma-of-thyroid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hutchinson-gilford-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hydatidiform-mole-benign 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperammonemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperammonemia-associated-with-n-acetylglutamate-synthase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypercalcemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypercalcemia-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypercalcemia-due-to-primary-hyperparathyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypercalcemia-in-parathyroid-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypercalcemia-in-primary-hyperparathyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypercortisolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperfibrinolysis-induced-hemorrhage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperhidrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperhidrosis-of-axilla 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperhidrosis-of-palms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperinsulinism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperkalemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperkeratosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperlipoproteinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypermagnesemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperparathyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperparathyroidism-secondary-to-chronic-renal-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperparathyroidism-secondary-to-chronic-renal-failure-with-dialysis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperphosphatemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperprolactinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypersomatotropic-gigantism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypersomnia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertension-as-add-on-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertension-with-left-ventricular-hypertrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertensive-emergencies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertensive-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertensive-urgency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperthyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertrichosis-of-eyelid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertriglyceridemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypertrophic-cardiomyopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperuricemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoalphalipoproteinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypocalcemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypocalcemia-from-end-stage-renal-disease-with-dialysis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypocalcemic-tetany 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoglycemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoglycemia-due-to-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoglycemic-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypogonadal-osteoporosis-in-males 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypogonadotropic-hypogonadism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypokalemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypokalemia-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypomagnesemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyponatremia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoparathyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypophosphatasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypophosphatemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypopituitarism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoplastic-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-due-to-antibacterial-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-biliary-fistula 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-celiac-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-cystic-fibrosis-of-the-pancreas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-factors-limiting-absorption-or-synthesis-of-vitamin-k 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-intestinal-resection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-obstructive-jaundice 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-regional-enteritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-sprue 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypoprothrombinemia-secondary-to-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyposelenemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyposensitization-to-allergens 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypotension-secondary-to-spinal-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypotension-associated-with-septic-shock 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypothyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypothyroidism-in-adult-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypothyroidism-in-neonates 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypothyroidism-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypovolemic-shock 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypozincemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hysterosalpingogram 2026-04-19 weekly 0.8 https://druglandscape.com/disease/idiopathic-pulmonary-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/idiopathic-generalized-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/idiopathic-hypereosinophilic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/idiopathic-hypertrophic-subaortic-stenosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/idiopathic-short-stature-in-pediatric-patients-2-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/idiopathic-thrombocytopenic-purpura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/if-you-need-to-know-the-indications-for-this-drug-i-recommend-checking-the-fda-website-or-other-reliable-sources 2026-04-19 weekly 0.8 https://druglandscape.com/disease/imaging-ovarian-cancer-and-malignant-lesions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/immune-thrombocytopenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/immunocompromised-adults-cll-hiv-autoimmune- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/impacted-cerumen 2026-04-19 weekly 0.8 https://druglandscape.com/disease/impetigo 2026-04-19 weekly 0.8 https://druglandscape.com/disease/impotence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/improvement-of-symptoms-in-patients-with-interstitial-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/improving-resorption-of-radiopaque-agents-in-subcutaneous-urography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/improving-hemodynamic-status-in-distributive-shock 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inactive-tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inborn-error-of-bile-acid-metabolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inclusion-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/incomplete-miscarriage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/incomplete-passage-of-stool 2026-04-19 weekly 0.8 https://druglandscape.com/disease/increased-intraocular-pressure-after-ocular-procedure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/increased-urinary-frequency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/increasing-the-dispersion-and-absorption-of-other-injected-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indapamide-and-chlorthalidone-to-reduce-urine-supersaturation-for-kidney-stone-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indication-1 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indication-2 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indication-3 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indication-not-found 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indication-under-phase-1-evaluation-not-specified- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indigestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/indolent-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induce-anterograde-amnesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-clinical-remission-in-adults-with-moderately-to-severely-active-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-final-follicular-maturation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-final-follicular-maturation-and-luteinization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-general-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-labor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-ovulation-and-pregnancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-ovulation-in-polycystic-ovarian-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-ovulation-in-unexplained-infertility 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-remission-in-adults-with-moderately-to-severely-active-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induction-of-spermatogenesis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/induratio-penis-plastica 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infantile-autism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infantile-spasms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-prevention-for-gi-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-prevention-from-tooth-extraction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-campylobacter-fetus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-cryptosporidium 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-fasciola 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-loa-loa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-onchocerca-volvulus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-pasteurella-multocida 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-schistosoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-strongyloides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-trichomonas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-trypanosoma-cruzi 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-uncinaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-by-larvae-of-trichinella-spiralis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-acinetobacter-spp-resistant-to-carbapenem-antimicrobial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-citrobacter-spp-resistant-to-carbapenem-antimicrobial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-enterococcus-spp-resistant-to-carbapenem-antimicrobial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-escherichia-coli-strain-resistant-to-carbapenem-antimicrobial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-helicobacter-pylori 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-klebsiella-spp-resistant-to-carbapenem-antimicrobial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-molluscum-contagiosum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-pseudomonas-aeruginosa-strain-resistant-to-carbapenem-antimicrobial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-serratia-spp-resistant-to-carbapenem-antimicrobial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-caused-by-carbapenem-resistant-acinetobacter-baumannii-calcoaceticus-complex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-due-to-clostridium-botulinum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-due-to-enterobacteriaceae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-due-to-escherichia-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-due-to-pseudomonas-aeruginosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-due-to-staphylococcus-aureus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-due-to-toxocara 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-due-to-anaerobic-bacteria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-of-biliary-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-of-bone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-of-skin-and-or-subcutaneous-tissue 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-protection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infectious-diarrheal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infectious-disease-of-abdomen 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infectious-disorder-of-joint 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infectious-inflammation-of-intestine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infective-blepharitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infective-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infective-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infective-laryngitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infective-otitis-externa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infective-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infertility-embryo-transfer-support- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infertility-secondary-to-progesterone-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infestation-by-phthirus-pubis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infestation-by-sarcoptes-scabiei-var-hominis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infiltrating-duct-carcinoma-of-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inflammatory-disease-of-female-pelvic-organs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inflammatory-bowel-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inflammatory-dermatosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-h1n1- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-h1n1-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-h1n1-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-h1n1-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-h1n1-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-h1n1-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-seasonal- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-seasonal-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-seasonal-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-seasonal-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-seasonal-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-seasonal-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-a-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-caused-by-pandemic-influenza-virus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-due-to-influenza-a-virus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-prevention-for-adults-and-children-6-years-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-protection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-vaccination 2026-04-19 weekly 0.8 https://druglandscape.com/disease/influenza-like-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inhalational-anthrax 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inhibition-of-lactation-procedure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/initial-insomnia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inner-ear-disturbance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inoperable-secondary-intractable-pneumothorax 2026-04-19 weekly 0.8 https://druglandscape.com/disease/insect-repellent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/insulinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intermittent-claudication 2026-04-19 weekly 0.8 https://druglandscape.com/disease/international-federation-of-gynecology-and-obstetrics-stage-finding-for-vulvar-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/interstitial-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intervertebral-disc-prolapse 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intestinal-infection-due-to-e-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intestinal-infection-due-to-pseudomonas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-anaerobic-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-bacteroides-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-candida-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-clostridium-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-e-coli-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-eubacterium-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-klebsiella-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-peptococcus-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-peptostreptococcus-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-operative-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intra-abdominal-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intractable-eczema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intractable-hiccups 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intrahepatic-cholangiocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intranasal-influenza-vaccine-for-active-immunization-against-influenza-disease-caused-by-influenza-virus-types-a-and-b-in-individuals-6-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intraosseous-venography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/intubation-of-gastrointestinal-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/invasive-aspergillosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/invasive-bladder-malignancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/invasive-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/invasive-mucormycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/invasive-pulmonary-aspergillosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/iridocyclitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/iritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/iron-deficiency-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/iron-overload 2026-04-19 weekly 0.8 https://druglandscape.com/disease/iron-supplement-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/irritable-bowel-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/irritable-bowel-syndrome-characterized-by-constipation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/irritable-bowel-syndrome-with-diarrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ischemic-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ischemic-heart-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ischemic-priapism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/islet-cell-hyperplasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/itching-of-ear 2026-04-19 weekly 0.8 https://druglandscape.com/disease/itching-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/japanese-encephalitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/japanese-encephalitis-je- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/japanese-encephalitis-je-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/joint-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis-with-enthesitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis-with-extended-oligoarticular-course 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis-with-oligoarticular-course 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis-with-persistent-oligoarticular-course 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis-with-polyarticular-course 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis-with-systemic-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-idiopathic-arthritis-extended-oligoarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-seronegative-polyarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/juvenile-seropositive-polyarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/kras-mutated-recurrent-low-grade-serous-ovarian-cancer-lgsoc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/kaposi-s-sarcoma-skin-lesions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/kaposi-s-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/kaposi-s-sarcoma-associated-with-aids 2026-04-19 weekly 0.8 https://druglandscape.com/disease/kawasaki-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/keloid-scar 2026-04-19 weekly 0.8 https://druglandscape.com/disease/keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/keratoconjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/keratoconjunctivitis-sicca 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-complicated-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-lung-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-nosocomial-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-pneumoniae-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-pneumoniae-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-pneumoniae-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-pyelonephritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klebsiella-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klinefelter-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/klinefelter-s-syndrome-xxy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/korsakoff-s-psychosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lhrh-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/labor-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lack-or-loss-of-sexual-desire 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lactose-intolerance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lamivudine-refractory-chronic-hepatitis-b 2026-04-19 weekly 0.8 https://druglandscape.com/disease/langerhans-cell-histiocytosis-disseminated 2026-04-19 weekly 0.8 https://druglandscape.com/disease/laron-type-isolated-somatotropin-defect 2026-04-19 weekly 0.8 https://druglandscape.com/disease/laryngeal-papillomatosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/late-latent-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/late-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/late-infantile-neuronal-ceroid-lipofuscinosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/late-onset-pompe-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/latent-bejel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/latent-early-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/latent-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/latent-yaws 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lateonset-pompe-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lateral-canthal-lines 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leber-s-optic-atrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/left-ventricular-cardiac-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/left-ventricular-thrombus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/legionella-pneumophila-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/legionella-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/legionnaires-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leiomyosarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leishmaniasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lennox-gastaut-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leprosy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leptin-receptor-lepr-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leukemia-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/leukopenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lichen-planus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lichen-simplex-chronicus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/life-or-functionthreatening-haemangioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/life-threatening-ventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/life-threatening-ventricular-arrhythmias 2026-04-19 weekly 0.8 https://druglandscape.com/disease/light-chain-al-amyloidosis-in-combination-with-bortezomib-cyclophosphamide-and-dexamethasone-in-newly-diagnosed-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lipodystrophy-due-to-human-immunodeficiency-virus-infection-and-antiretroviral-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/liposarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/listeria-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/listerial-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/listeriosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/liver-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/liver-transplant-rejection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/local-anesthesia-for-endotracheal-intubation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/local-anesthesia-for-ophthalmologic-procedure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/local-anesthesia-for-urethral-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/local-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/local-anesthesia-by-infiltration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/local-anesthetic-intrathecal-block 2026-04-19 weekly 0.8 https://druglandscape.com/disease/localization-related-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-nsclc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-have-a-pd-l1-combined-positive-score-cps-10-as-determined-by-an-fda-approved-test-in-combination-with-axitinib- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-have-a-pd-l1-combined-positive-score-cps-10-as-determined-by-an-fda-approved-test-in-combination-with-lenvatinib- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-have-a-pd-l1-combined-positive-score-cps-10-as-determined-by-an-fda-approved-test-in-combination-with-pembrolizumab-and-lenvatinib-in-patients-with-a-pd-l1-cps-10-as-determined-by-an-fda-approved-test- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-have-a-pd-l1-combined-positive-score-cps-10-as-determined-by-an-fda-approved-test-in-combination-with-pembrolizumab-and-lenvatinib- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-have-a-pd-l1-combined-positive-score-cps-10-as-determined-by-an-fda-approved-test- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-anaplastic-thyroid-cancer-atc-with-braf-v600e-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-squamous-cell-carcinomas-of-the-head-and-neck-excluding-lip-in-combination-with-concurrent-chemoradiation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/long-qt-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/long-term-maintenance-therapy-for-bilateral-micro-or-macronodular-adrenal-hyperplasia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/long-term-maintenance-therapy-for-discrete-aldosterone-producing-adrenal-adenomas-in-non-surgical-candidates 2026-04-19 weekly 0.8 https://druglandscape.com/disease/louse-borne-typhus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/low-blood-pressure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/low-cardiac-output-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/low-grade-b-cell-non-hodgkin-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lower-abdominal-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lower-limb-spasticity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lower-respiratory-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lower-urinary-tract-infectious-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lowering-blood-pressure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lumbago 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lung-cancer-squamous-cell 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lung-deposition-characterization-in-cystic-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/luteal-phase-support 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lyme-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymph-node-positive-colorectal-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphangiectasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphangioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphangiomatosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphatic-filariasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphogranuloma-venereum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphomatous-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lymphoscintigraphy-in-cervical-cancer-uterine-neoplasms-vulvar-cancer-and-head-and-neck-canccer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lysosomal-alpha-1-4-glucosidase-deficiency-infantile-onset 2026-04-19 weekly 0.8 https://druglandscape.com/disease/l-ffler-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/m-lymphoplasmacytic 2026-04-19 weekly 0.8 https://druglandscape.com/disease/m-tuberculosis-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mri-of-the-central-nervous-system-cns-in-adults-and-pediatric-patients-including-term-neonates-to-visualize-lesions-with-abnormal-blood-brain-barrier-or-abnormal-vascularity-of-the-brain-spine-and-associated-tissues 2026-04-19 weekly 0.8 https://druglandscape.com/disease/macular-edema-due-to-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/magnetic-resonance-angiography-mra-to-evaluate-adults-with-known-or-suspected-aorto-ilio-femoral-occlusive-vascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/magnetic-resonance-angiography-mra-to-evaluate-adults-with-known-or-suspected-renal-occlusive-vascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/magnetic-resonance-imaging 2026-04-19 weekly 0.8 https://druglandscape.com/disease/magnetic-resonance-imaging-of-liver 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintain-patency-of-indwelling-vascular-catheter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-healing-duodenal-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-healing-erosive-esophagitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-healing-gastric-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-healing-gastroesophageal-reflux 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-normal-sinus-rhythm-delay-in-af-afl-recurrence- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-clinical-response-and-endoscopic-remission-in-adults-with-moderately-to-severely-active-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-clinical-response-and-endoscopic-remission-in-adults-with-moderately-to-severely-active-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-clinical-response-and-remission-in-adults-with-moderately-to-severely-active-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-clinical-response-and-remission-in-adults-with-moderately-to-severely-active-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-of-intraoperative-mydriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-therapy-of-unresectable-urothelial-carcinoma-in-patients-who-have-received-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-treatment-of-asthma-as-prophylactic-therapy-in-patients-aged-4-years-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/major-depressive-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/major-depressive-disorder-mdd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/major-nerve-block-for-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malaria-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/male-patterned-baldness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/male-hypogonadism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-hyperthermia-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-melanoma-with-braf-v600e-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-melanoma-with-braf-v600k-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-neoplasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-epithelial-tumor-of-ovary 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-essential-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-glaucoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-glioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-hyperthermia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-lymphoma-small-lymphocytic 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-lymphoma-large-b-cell-diffuse 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-mesothelioma-of-pleura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-neoplasm-of-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-neoplasm-of-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-neoplasm-of-colon-and-or-rectum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-neoplasm-of-common-bile-duct-carcinoma- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-neoplasm-of-liver 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-otitis-externa-due-to-pseudomonas-aeruginosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-cervix 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-colon 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-fallopian-tube 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-head-and-or-neck 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-ovary 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-pancreas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-penis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-peritoneum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-prostate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-stomach 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-testis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-thyroid-gland 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignant-tumor-of-vulva 2026-04-19 weekly 0.8 https://druglandscape.com/disease/management-of-anxiety-disorders 2026-04-19 weekly 0.8 https://druglandscape.com/disease/management-of-pain-severe-enough-to-require-an-opioid-analgesic 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mantle-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/marginal-zone-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maroteaux-lamy-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mast-cell-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mastocytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mastoidectomy-cavity-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/measles-mumps-and-rubella 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mechanical-heart-valve-thrombosis-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/medullary-thyroid-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/megakaryocyte-erythroid-potent-protocadherin-related-protein-mepep-associated-hemophagocytic-lymphohistiocytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/megaloblastic-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/megaloblastic-anemia-due-to-folate-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meibomian-gland-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meibomianitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/memory-impairment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningeal-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningitis-due-to-bacteroides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningitis-due-to-klebsiella-mobilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-b 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-b-menb-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-carrier-state 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-conjugate-menacwy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-conjugate-menacwy-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menacwy-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menacwy-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menacwy-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menacwy-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menacwy-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menb-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menb-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menb-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menb-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-disease-menb-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/meningococcus-carrier 2026-04-19 weekly 0.8 https://druglandscape.com/disease/menopausal-flushing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/menopause 2026-04-19 weekly 0.8 https://druglandscape.com/disease/menorrhagia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/menstrual-disorders 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mercury-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/merkel-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mesothelioma 2026-03-25 weekly 0.8 https://druglandscape.com/disease/metastasis-from-malignant-tumor-of-colon 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastasis-from-malignant-tumor-of-prostate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastasis-from-malignant-tumor-of-thyroid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-alk-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-breast-cancer-progression-post-antiestrogen-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-breast-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-castration-sensitive-prostate-cancer-mcspc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-gastric-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-non-keratinizing-nasopharyngeal-carcinoma-with-disease-progression-on-or-after-platinum-based-chemotherapy-and-at-least-one-other-prior-line-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-prostate-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-wilms-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-basal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-bone-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-bronchogenic-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-carcinoma-to-biliary-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-carcinoma-to-colon 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-castration-resistant-prostate-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-castration-resistant-prostate-cancer-crpc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-castration-resistant-prostate-cancer-mcrpc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-castration-resistant-prostate-cancer-mcrpc-with-brca1-brca2-or-atm-gene-mutations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-gastric-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-high-risk-castration-sensitive-prostate-cancer-cspc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-high-risk-castration-sensitive-prostate-cancer-mhspc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-human-epidermal-growth-factor-2-positive-carcinoma-of-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-malignant-melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-neuroblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-non-small-cell-lung-cancer-nsclc-with-braf-v600e-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-non-small-cell-lung-cancer-with-no-anaplastic-lymphoma-kinase-genomic-tumor-aberrations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-nonsmall-cell-lung-cancer-with-no-sensitising-egfr-mutation-or-alk-translocation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-ovarian-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-prostate-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-renal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-soft-tissue-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-thyroid-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-transitional-cell-bladder-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-urothelial-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/methemoglobinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/methicillin-resistant-staphylococcus-aureus-nasal-colonization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/methotrexate-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab-and-nivolumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-pembrolizumab-and-nivolumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-pembrolizumab-and-nivolumab-and-ipilimumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-bevacizumab-and-cetuximab-and-panitumumab-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-fluorouracil-leucovorin-irinotecan-and-oxaliplatin-mfolfox6-and-avelumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-pembrolizumab-and-nivolumab-and-ipilimumab-and-pembrolizumab-and-nivolumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer-in-adults-in-combination-with-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microsatellite-instability-high-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microscopic-polyangiitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/microscopic-polyarteritis-nodosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/migraine-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/migraine-with-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/migraine-without-aura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mild-cognitive-impairment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mild-hypothyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mild-to-moderate-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/miliary-tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mineral-deficiency-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mineral-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-bacterial-skin-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-skin-wound-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/miscarriage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/miscarriage-with-sepsis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mixed-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mixed-gonococcal-and-chlamydia-infection-of-the-cervix 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mixed-gonococcal-and-chlamydia-infection-of-the-urethra 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mixed-anxiety-and-depressive-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mixed-bipolar-i-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mixed-hyperlipidemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mixedcell-type-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-alzheimer-s-type-dementia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-juvenile-idiopathic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-plaque-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-fistulizing-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease-and-fistulizing-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease-and-fistulizing-disease-and-axial-involvement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis-and-atopic-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis-and-atopic-dermatitis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis-and-atopic-dermatitis-and-hidradenitis-suppurativa-and-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-rheumatoid-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-alopecia-areata 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-alopecia-areata-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-crohn-s-disease-and-rheumatoid-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-rheumatoid-arthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-rheumatoid-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ankylosing-spondylitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-anogenital-pruritus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-anogenital-pruritus-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-in-adults-who-have-had-an-inadequate-response-or-intolerance-to-one-or-more-biologics-or-who-are-candidates-for-systemic-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-in-children-12-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-in-children-aged-12-years-and-older-who-have-had-an-inadequate-response-or-intolerance-to-one-or-more-biologics-or-who-are-candidates-for-systemic-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis-and-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axial-spondyloarthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axillary-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-axillary-hidradenitis-suppurativa-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-bullous-pemphigoid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-bullous-pemphigoid-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-chronic-spontaneous-urticaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-chronic-spontaneous-urticaria-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-epidermolysis-bullosa-acquisita 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-epidermolysis-bullosa-acquisita-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-erythromelalgia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-erythromelalgia-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-generalized-pustular-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-generalized-pustular-psoriasis-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-and-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-and-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-hidradenitis-suppurativa-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-intertrigo 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-intertrigo-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-lichen-sclerosus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-lichen-sclerosus-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-lichen-simplex-chronicus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-lichen-simplex-chronicus-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-mucous-membrane-pemphigoid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-mucous-membrane-pemphigoid-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis-and-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-non-radiographic-axial-spondyloarthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-palmoplantar-pustulosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-palmoplantar-pustulosis-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-pemphigus-vulgaris 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-pemphigus-vulgaris-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-plaque-psoriasis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-plaque-psoriasis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-plaque-psoriasis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-plaque-psoriasis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-plaque-psoriasis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-plaque-psoriasis-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-prurigo-nodularis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-prurigo-nodularis-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-ankylosing-spondylitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-ankylosing-spondylitis-and-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-ankylosing-spondylitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-psoriatic-arthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-psoriatic-arthritis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-psoriatic-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-rheumatoid-arthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-rheumatoid-arthritis-and-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-rheumatoid-arthritis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-rheumatoid-arthritis-and-ankylosing-spondylitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-rheumatoid-arthritis-and-ankylosing-spondylitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-rheumatoid-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-crohn-s-disease-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-crohn-s-disease-ulcerative-colitis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-ulcerative-colitis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-ulcerative-colitis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-ulcerative-colitis-rheumatoid-arthritis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-ulcerative-colitis-rheumatoid-arthritis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-ulcerative-colitis-rheumatoid-arthritis-hidradenitis-suppurativa-and-atopic-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-crohn-s-disease-ulcerative-colitis-rheumatoid-arthritis-hidradenitis-suppurativa-atopic-dermatitis-and-plaque-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ankylosing-spondylitis-ulcerative-colitis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-rheumatoid-arthritis-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriasis-ulcerative-colitis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-crohn-s-disease-and-rheumatoid-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-ankylosing-spondylitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-ankylosing-spondylitis-and-rheumatoid-arthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-ankylosing-spondylitis-and-rheumatoid-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-ankylosing-spondylitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-axial-involvement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-ankylosing-spondylitis-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-ankylosing-spondylitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-psoriatic-arthritis-ankylosing-spondylitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-ankylosing-spondylitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-ankylosing-spondylitis-and-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-ankylosing-spondylitis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-rheumatoid-arthritis-ankylosing-spondylitis-crohn-s-disease-and-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-systemic-lupus-erythematosus-sle- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-crohn-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-fistulizing-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease-and-fistulizing-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease-and-fistulizing-disease-and-axial-involvement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis-and-atopic-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis-and-atopic-dermatitis-and-hidradenitis-suppurativa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-perianal-disease-and-fistulizing-disease-and-axial-involvement-and-psoriatic-arthritis-and-atopic-dermatitis-and-hidradenitis-suppurativa-and-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-ulcerative-colitis-and-rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-vitiligo 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-vitiligo-in-infants-and-children 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-active-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-severe-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-severe-to-severe-infections-of-the-upper-respiratory-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-to-severely-active-crohn-s-disease-in-adults-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-to-severely-active-rheumatoid-arthritis-in-adults-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-to-severely-active-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-to-severely-active-ulcerative-colitis-in-adults-with-inadequate-response-or-intolerance-to-tnf-blockers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/molybdenum-cofactor-deficiency-type-a 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moraxella-catarrhalis-acute-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moraxella-catarrhalis-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moraxella-catarrhalis-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/morganella-morganii-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/morganella-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/morphea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/motion-sickness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/motor-cortex-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mottle-hyperpigmentation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mouth-infection-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mouth-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucocutaneous-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucopolysaccharidosis-type-ii 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucopolysaccharidosis-mps-i 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucopolysaccharidosis-mps-ii 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucopolysaccharidosis-mps-iv-a 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucopolysaccharidosis-mps-vii 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucormycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mucositis-following-radiation-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multibacillary-leprosy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multidrug-resistant-hiv-1-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-as-monotherapy-in-patients-who-have-received-at-least-three-prior-lines-of-therapy-including-a-proteasome-inhibitor-pi-and-an-immunomodulatory-agent-or-who-are-double-refractory-to-a-pi-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-bortezomib-and-dexamethasone-in-patients-who-have-received-at-least-one-prior-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-for-induction-and-consolidation-in-newly-diagnosed-patients-who-are-eligible-for-autologous-stem-cell-transplant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-in-newly-diagnosed-patients-who-are-ineligible-for-autologous-stem-cell-transplant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-bortezomib-melphalan-and-prednisone-in-newly-diagnosed-patients-who-are-ineligible-for-autologous-stem-cell-transplant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-bortezomib-thalidomide-and-dexamethasone-in-newly-diagnosed-patients-who-are-eligible-for-autologous-stem-cell-transplant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-carfilzomib-and-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-one-to-three-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-lenalidomide-and-dexamethasone-in-newly-diagnosed-patients-who-are-ineligible-for-autologous-stem-cell-transplant-and-in-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-myeloma-in-combination-with-pomalidomide-and-dexamethasone-in-patients-who-have-received-at-least-one-prior-line-of-therapy-including-lenalidomide-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-endocrine-adenomas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/multiple-risk-factors-for-coronary-heart-disease-chd-but-without-clinically-evident-chd 2026-04-19 weekly 0.8 https://druglandscape.com/disease/murine-typhus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscarine-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-spasm-with-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-spasticity-due-to-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-spasticity-of-cerebral-origin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-relaxation-function 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-spasticity-of-spinal-origin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-invasive-bladder-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myasthenia-gravis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mycosis-fungoides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mycotic-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myelodysplastic-syndromes 2026-03-25 weekly 0.8 https://druglandscape.com/disease/myelodysplastic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myelodysplastic-myeloproliferative-diseases-with-re-arrangements-of-the-gene-for-platelet-derived-growth-factor-receptor-pdgfr- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myelofibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myelofibrosis-mf-in-adult-patients-who-are-refractory-or-resistant-to-other-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myeloproliferative-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myocardial-infarction-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myocardial-perfusion-imaging-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myocardial-reinfarction-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myocardial-infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myoclonic-epilepsy-adjunct-treatment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myoclonic-seizure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myotonic-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myxedema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myxedema-coma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/m-ni-re-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nafld-nash-combination-therapy-with-dgat2i- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nash-with-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsaid-induced-gastric-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsclc-pd-l1- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsclc-pd-l1-post-platinum- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsclc-adjuvant- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsclc-neoadjuvant- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsclc-nonsquamous- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsclc-squamous- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ntrk-fusion-gene-positive-advanced-or-recurrent-solid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ntrk-gene-fusion-positive-solid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nyha-class-iii-iv-heart-failure-with-reduced-ejection-fraction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/narcoanalysis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/narcolepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nasal-congestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nasal-discharge 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nasal-polyp 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/necator-americanus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neckshoulderarm-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/necrobiosis-lipoidica-diabeticorum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/necrotizing-fasciitis-streptococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neisseria-gonorrhea-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neisseria-meningitidis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neisseria-meningitidis-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neonatal-group-b-streptococcal-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neonatal-hemorrhagic-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neonatal-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neonatal-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neonatal-hypocalcemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neonatal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neonatal-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neoplasm-metastasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neoplasm-of-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neoplasm-of-head-and-neck 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neoplasm-of-prostate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neovascular-glaucoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nephroblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nephrotic-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuralgia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuroblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuroendocrine-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neurogenic-detrusor-overactivity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neurogenic-bladder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuroleptic-induced-parkinsonism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neurology 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuromuscular-block-due-to-nondepolarizing-drug 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuromyelitis-optica 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuropathic-diabetic-ulcer-foot 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuropathic-pain-associated-with-diabetic-peripheral-neuropathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neuropathic-pain-associated-with-spinal-cord-injury 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neurosyphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/neurotrophic-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/niacin-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nicotine-withdrawal-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nicotine-dependence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/niemann-pick-disease-type-c-npc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/niemann-pick-disease-type-a 2026-04-19 weekly 0.8 https://druglandscape.com/disease/niemann-pick-disease-type-b 2026-04-19 weekly 0.8 https://druglandscape.com/disease/niemann-pick-disease-type-c 2026-04-19 weekly 0.8 https://druglandscape.com/disease/no-fda-approved-indications-found-for-pf-07999415 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nocardiosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nocturia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nocturnal-enuresis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-hodgkin-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-hodgkin-s-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-hyperkeratotic-actinic-keratoses 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-q-wave-myocardial-infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-radiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-nsclc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nsclc 2026-03-25 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-nsclc-with-egfr-exon-20-insertion-mutations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-nsclc-with-high-pd-l1-expression-tumor-proportion-score-tps-50-as-monotherapy-pembrolizumab-in-combination-with-pemetrexed-and-platinum-pemetrexed-platinum-in-patients-with-a-pd-l1-tps-1-as-determined-by-an-fda-approved-test- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-nsclc-with-high-pd-l1-expression-50-as-a-monotherapy-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-nsclc-with-high-pd-l1-expression-50-as-a-monotherapy-in-adults-and-in-combination-with-pembrolizumab-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-nsclc-with-high-pd-l1-expression-50-as-determined-by-an-fda-approved-test-in-patients-whose-tumors-have-progressed-during-or-following-platinum-containing-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-allergic-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-infectious-posterior-uveitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-infectious-anterior-uveitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-infectious-intermediate-posterior-and-panuveitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-infective-diarrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-productive-cough 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-with-mutation-in-epidermal-growth-factor-receptor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-without-mutation-in-epidermal-growth-factor-receptor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-negative-for-epidermal-growth-factor-receptor-expression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-positive-for-epidermal-growth-factor-receptor-expression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-valvular-atrial-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonq-wave-myocardial-infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonalcoholic-fatty-liver-disease-nafld- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonalcoholic-steatohepatitis-nash- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nongonococcal-urethritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonpsychotic-anxiety 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonradiographic-axial-spondyloarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonsmall-cell-lung-cancer-without-mutation-in-epidermal-growth-factor-receptor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonsquamous-nonsmall-cell-neoplasm-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nontuberculous-mycobacterial-pulmonary-disease-caused-by-amikacin-sensitive-mycobacteriumavium-complex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonulcer-dyspepsia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonunion-of-fracture 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nonvalvular-atrial-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/noonan-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nosocomial-pneumonia-due-to-escherichia-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nosocomial-pneumonia-due-to-haemophilus-influenzae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nosocomial-pneumonia-due-to-klebsiella-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nosocomial-pneumonia-due-to-methicillin-sensitive-staphylococcus-aureus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nosocomial-pneumonia-due-to-serratia-marcescens 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nosocomial-pneumonia-due-to-streptococcus-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nosocomial-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/not-for-treatment-of-diabetic-ketoacidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/not-for-treatment-of-type-1-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nuclear-medicine-imaging-procedure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nummular-eczema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nutritional-deficiency-associated-with-aids 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nutritional-support 2026-04-19 weekly 0.8 https://druglandscape.com/disease/obesity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/obsessive-compulsive-disorder-ocd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/obsessive-compulsive-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/obstruction-of-bile-duct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/obstructive-hyperbilirubinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/obstructive-hypertrophic-cardiomyopathy-hcm- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ocular-itching 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ocular-histoplasmosis-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ocular-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ocular-rosacea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/oncology 2026-04-19 weekly 0.8 https://druglandscape.com/disease/onychomycosis-due-to-trichophyton-mentagrophytes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/onychomycosis-due-to-dermatophyte 2026-04-19 weekly 0.8 https://druglandscape.com/disease/onychomycosis-of-fingernails 2026-04-19 weekly 0.8 https://druglandscape.com/disease/onychomycosis-of-toenails 2026-04-19 weekly 0.8 https://druglandscape.com/disease/open-heart-surgery-infection-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/open-angle-glaucoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/operation-on-lens 2026-04-19 weekly 0.8 https://druglandscape.com/disease/opiate-induced-respiratory-depression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/opioid-dependence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/opioid-withdrawal 2026-04-19 weekly 0.8 https://druglandscape.com/disease/opisthorchiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/opportunistic-fungal-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/orchiectomy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/orchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/organic-cardiac-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/organophosphate-poisoning 2026-04-19 weekly 0.8 https://druglandscape.com/disease/organophosphorous-overdose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ornithine-carbamyltransferase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ornithosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/oropharyngeal-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/orthostatic-hypotension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osmotic-laxative 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteitis-deformans 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoarthritis-in-patients-at-high-ulcer-risk 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoarthritis-of-hip 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoarthritis-of-knee 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoarthritis-of-the-hip 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoarthritis-of-the-knee 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoarthrosis-of-the-knee 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteolytic-bone-metastases-of-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteolytic-lesions-of-multiple-myeloma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteomalacia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteomyelitis-due-to-staphylococcus-aureus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/osteosarcoma-of-bone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/other-drug-induced-hypoprothrombinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-eczema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-seborrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-acinetobacter-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-enterobacter-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-haemophilus-influenzae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-klebsiella-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-moraxella-branhamella-catarrhalis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-pseudomonas-aeruginosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-serratia-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-staphylococcus-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-streptococcus-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-externa-caused-by-streptococcus-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-acinetobacter-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-enterobacter-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-klebsiella-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-moraxella-branhamella-catarrhalis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-pseudomonas-aeruginosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-serratia-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-staphylococcus-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-streptococcus-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-caused-by-streptococcus-spp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/otitis-media-due-to-susceptible-streptococcus-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ovale-malaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ovarian-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/ovarian-germ-cell-tumor-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ovarian-neoplasms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ovarian-deficiency-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/overactive-bladder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/overdose-of-opiate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ovulation-induction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pik3ca-related-overgrowth-spectrum-pros- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psma-positive-metastatic-castration-resistant-prostate-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain-associated-with-endometriosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain-associated-with-fibromyalgia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain-due-to-osteoblastic-bone-metastasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain-in-patients-for-whom-alternative-treatment-options-are-ineffective 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain-in-patients-for-whom-alternative-treatment-options-are-not-tolerated 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pain-in-patients-for-whom-alternative-treatment-options-would-be-otherwise-inadequate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/palmoplantar-pustulosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pancreatic-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/pancreatic-neuroendocrine-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pancreatic-function-test 2026-04-19 weekly 0.8 https://druglandscape.com/disease/panic-disorder-pd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/panic-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pantothenic-acid-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/papillary-thyroid-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/papulopustular-rosacea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paracoccidioidomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paraganglioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paralytic-ileus-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paralytic-ileus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paraneoplastic-hyponatremia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/parathyroid-carcinoma-with-hypercalcemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paratyphoid-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/parenteral-nutrition-support-in-critically-ill-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/parkinson-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/parkinsons-disease 2026-03-25 weekly 0.8 https://druglandscape.com/disease/parkinsonian-syndromes-ps- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/parkinsonism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paronychia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paroxysmal-atrial-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paroxysmal-atrial-flutter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paroxysmal-nocturnal-hemoglobinuria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paroxysmal-supraventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/partial-central-diabetes-insipidus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/partial-epilepsy-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/partial-seizure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/partial-seizures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pasteurella-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/patent-ductus-arteriosus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pathologic-myopia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pathological-gastric-hypersecretory-condition 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pathological-hypersecretory-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pediatric-ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pediculosis-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pediculosis-capitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pediculosis-corporis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pellagra 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pelvic-inflammatory-disease-with-neisseria-gonorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pelvic-organ-prolapse 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pelvic-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pelvic-inflammatory-disease-due-to-mycoplasma-hominis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pembrolizumab-plus-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pembrolizumab-plus-chemotherapy-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-who-are-not-eligible-for-any-platinum-containing-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pemphigus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pemphigus-foliaceus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pemphigus-vulgaris 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptic-reflux-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptic-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-liver-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptococcus-tubo-ovarian-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-complicated-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-liver-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-postpartum-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-septic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-tubo-ovarian-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peptostreptococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/percutaneous-coronary-intervention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/perennial-allergic-rhinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/perforation-of-cornea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pericardial-malignant-effusions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/periodontitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/periodontitis-adjunct-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/perioperative-mydriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/perioperative-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/perioperative-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-arterial-thromboembolism-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-arteriography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-edema-due-to-chronic-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-mobilization-of-hematopoietic-stem-cells 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-arterial-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-arterial-embolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-neuropathic-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-vascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peripheral-venous-insufficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peritoneal-malignant-effusions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/peritonsillar-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pernicious-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/persistent-pulmonary-hypertension-of-the-newborn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pertussis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pf-07941944-s-indications-are-not-publicly-available-or-i-do-not-have-access-to-the-information 2026-04-19 weekly 0.8 https://druglandscape.com/disease/phantom-limb-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pharyngitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pharyngitis-and-or-tonsillitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pharyngitis-tonsillitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pheochromocytoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pheochromocytoma-adjunct-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/philadelphia-chromosome-positive-chronic-myelocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/philadelphia-chromosome-positive-chronic-myeloid-leukemia-ph-cml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/photodynamic-therapy-for-abscesses 2026-04-19 weekly 0.8 https://druglandscape.com/disease/photosensitivity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pinta 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pituitary-function-studies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pituitary-thyroid-stimulating-hormone-tsh-suppression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pituitary-dwarfism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pituitary-dependent-cushing-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pityriasis-simplex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pityriasis-versicolor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/plague 2026-04-19 weekly 0.8 https://druglandscape.com/disease/plaque-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/plaquenil-resistant-or-intolerant-adult-patients-with-cutaneous-t-cell-lymphoma-ctcl-who-have-had-an-inadequate-response-or-are-intolerant-to-at-least-one-prior-systemic-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/plasmodium-falciparum-malaria-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/plasmodium-malariae-malaria-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/plasmodium-ovale-malaria-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/platelet-aggregation-inhibition 2026-04-19 weekly 0.8 https://druglandscape.com/disease/platinum-resistant-refractory-high-grade-serous-ovarian-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/platonicus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/please-note-that-i-am-unable-to-verify-the-indications-for-this-drug 2026-04-19 weekly 0.8 https://druglandscape.com/disease/please-note-that-this-information-might-not-be-up-to-date-or-accurate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pleural-malignant-effusions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-acute-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-immunization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-conjugate-pcv- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-conjugate-pcv-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-disease-pcv-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-disease-pcv-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-disease-pcv-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-disease-pcv-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-disease-pcv-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-infectious-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-pharyngitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcal-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumococcus-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumocystis-carinii-pneumonia-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumocystosis-jiroveci-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-caused-by-chlamydia-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-caused-by-severe-acute-respiratory-syndrome-coronavirus-2 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-due-to-escherichia-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-due-to-gram-negative-bacteria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-due-to-klebsiella-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-due-to-mycoplasma-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-due-to-pseudomonas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-due-to-staphylococcus-aureus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonia-due-to-streptococcus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pneumonic-plague 2026-04-19 weekly 0.8 https://druglandscape.com/disease/poisoning-by-acetaminophen 2026-04-19 weekly 0.8 https://druglandscape.com/disease/poisoning-by-digitalis-glycoside 2026-04-19 weekly 0.8 https://druglandscape.com/disease/poisoning-by-iron-and-or-its-compounds 2026-04-19 weekly 0.8 https://druglandscape.com/disease/poisoning-by-opiate-analgesic-drug 2026-04-19 weekly 0.8 https://druglandscape.com/disease/poisoning-due-to-nerve-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polyarteritis-nodosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polyarticular-juvenile-idiopathic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polyarticular-juvenile-idiopathic-arthritis-pjia- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polycystic-kidney-disease-adult-type 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polycythemia-vera 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polycythemia-vera-pv-in-adult-patients-who-are-refractory-or-resistant-to-other-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polycythemia-vera-and-essential-thrombocythemia-thromboembolism-prevention- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polymyalgia-rheumatica 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polyneuropathy-in-amyloidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polyuria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pompe-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/positron-emission-tomography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/positron-emission-tomography-with-computed-tomography-of-whole-body-using-gallium-68-ga-dotatate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-traumatic-osteoarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-anesthesia-respiratory-depression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-gynecologic-infection-due-to-bacteroides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-gynecologic-infection-due-to-porphyromonas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-gynecologic-infection-due-to-prevotella 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-gynecologic-infection-due-to-streptococcus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-gynecological-infection-due-to-e-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-gynecological-peptostreptococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-ocular-inflammation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-op-photophobia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-operative-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-operative-vaginal-cuff-peptostreptococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-dural-puncture-headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-essential-thrombocythaemia-myelofibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-exposure-prophylaxis-of-influenza 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-operative-metabolic-support 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-polycythaemia-vera-myelofibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-transplant-cytomegalovirus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postabortal-hemorrhage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postcoital-contraception 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postencephalitic-parkinsonism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/posterior-synechiae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postherpetic-neuralgia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postmenopausal-osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postnatal-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-atrial-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-ocular-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-recovery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-adjuvant-therapy-for-urothelial-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-ileus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-ocular-pain-in-intraocular-lens-replacement-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postoperative-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-endomyometritis-due-to-bacteroides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-endomyometritis-due-to-e-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-endomyometritis-due-to-peptostreptococcus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-endomyometritis-due-to-porphyromonas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-endomyometritis-due-to-prevotella 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-endomyometritis-due-to-streptococcus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-depression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-hemorrhage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postpartum-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/postsurgical-hemorrhage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/posttraumatic-stress-disorder-ptsd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/posttraumatic-stress-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prader-willi-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pre-b-cell-acute-lymphoblastic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pre-op-apprehension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/precocious-puberty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/precursor-t-cell-lymphoblastic-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pregnancy-maintenance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pregnancy-termination 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pregnancy-with-abortive-outcome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pregnancy-function 2026-04-19 weekly 0.8 https://druglandscape.com/disease/premature-luteinizing-hormone-surges 2026-04-19 weekly 0.8 https://druglandscape.com/disease/premature-ejaculation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/premature-labor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/premenstrual-dysphoric-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preoperative-anxiety 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preoperative-bowel-preparation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preoperative-disinfection-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preoperative-sedation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prepubertal-cryptorchidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preterm-labor-delay-of-preterm-birth- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevent-minor-bacterial-skin-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevent-pregnancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-blood-clots-forming-in-hardened-blood-vessels 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-bacterial-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-bacterial-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-breast-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-bronchospasm-with-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-bronchospasms-with-emphysema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cmv-disease-after-cardiac-transplantation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cmv-disease-after-kidney-transplantation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cmv-disease-after-kidney-pancreas-transplantation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cmv-disease-after-organ-transplant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cmv-disease-in-advanced-hiv-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-adults-and-pediatric-patients-12-years-of-age-and-older-who-are-at-high-risk-of-covid-19 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-booster-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-for-the-janssen-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-who-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-who-have-previously-received-primary-vaccination-with-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-who-have-previously-received-primary-vaccination-with-any-authorized-covid-19-vaccine-and-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-with-certain-health-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-with-certain-underlying-medical-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-with-weakened-immune-systems 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-fourth-dose-administered-at-least-2-months-after-the-third-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-second-booster-dose-administered-at-least-4-months-after-the-first-booster-dose-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine-in-individuals-who-received-a-second-booster-dose-of-a-different-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-as-a-third-dose-administered-at-least-2-months-after-either-the-second-dose-of-a-2-dose-series-or-the-first-dose-of-a-single-dose-regimen 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine-and-when-administered-to-individuals-who-have-completed-primary-vaccination-with-comirnaty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-fifth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-fourth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-seventh-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-sixth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-a-third-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-12-years-of-age-and-older-when-administered-as-an-eighth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-as-a-booster-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-for-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-who-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-who-have-previously-received-primary-vaccination-with-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-who-have-previously-received-primary-vaccination-with-any-authorized-covid-19-vaccine-and-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-with-certain-health-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-with-certain-underlying-medical-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-with-weakened-immune-systems 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine-and-when-administered-to-individuals-who-have-completed-primary-vaccination-with-comirnaty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-fifth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-fourth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-seventh-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-sixth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-third-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-an-eighth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-for-the-moderna-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-for-the-novavax-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-who-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-who-have-previously-received-primary-vaccination-with-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-who-have-previously-received-primary-vaccination-with-any-authorized-covid-19-vaccine-and-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-with-certain-underlying-medical-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-with-weakened-immune-systems 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-comirnaty-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-booster-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine-after-completion-of-primary-vaccination-with-any-covid-19-vaccine-when-administered-at-least-2-months-after-the-completion-of-primary-vaccination-or-any-subsequent-booster-dose-with-any-covid-19-vaccine-and-at-least-2-months-after-administration-of-a-prior-booster-dose-with-any-covid-19-vaccine-and-when-administered-to-individuals-who-have-completed-primary-vaccination-with-comirnaty 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-fifth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-fourth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-seventh-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-sixth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-a-third-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-of-age-and-older-when-administered-as-an-eighth-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-through-11-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-through-4-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-through-4-years-of-age-as-a-booster-dose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-covid-19-in-individuals-6-months-through-4-years-of-age-with-certain-health-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cancer-chemotherapy-induced-renal-impairment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cardiac-ischemia-in-unstable-angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cardiac-transplant-rejection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cerebral-thrombosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-chemotherapy-induced-hemorrhagic-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-disseminated-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-glucocorticoid-induced-osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-12-through-15-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-12-through-59-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-12-through-71-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-12-through-72-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-15-through-18-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-59-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-60-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-61-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-62-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-63-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-64-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-65-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-66-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-67-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-68-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-69-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-70-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-71-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-18-through-72-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-59-through-71-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-haemophilus-influenzae-type-b-hib-disease-caused-by-haemophilus-influenzae-type-b-hib-in-children-6-weeks-through-18-months-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-hypotension-during-spinal-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-infection-from-transurethral-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-infection-in-transrectal-prostate-biopsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-ischemic-complications-of-non-q-wave-mi 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-kidney-transplant-rejection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-liver-transplant-rejection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-luteinizing-hormone-surge-when-undergoing-controlled-ovarian-hyperstimulation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-maternal-fetal-transmission-of-hiv 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-meningococcal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-motion-sickness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-nsaid-induced-gastric-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-neonatal-hemorrhagic-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-neonatal-ophthalmia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-ocular-surgery-induced-miosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-oropharyngeal-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-paroxysmal-supraventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-perioperative-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-post-operative-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-posterior-synechiae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-premature-labor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children-at-high-risk-of-rsv-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-rsv-lower-respiratory-tract-disease-in-neonates-at-high-risk-of-rsv-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-radiation-therapy-induced-mucositis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-radiation-induced-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-recurrent-venous-thrombosis-associated-with-malignancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-seasonal-affective-disorder-sad- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-seizures-following-cranial-trauma-or-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-thromboembolism-with-chronic-atrial-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-transient-ischemic-attacks 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-transplant-rejection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-ventricular-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-vitamin-b12-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-xerostomia-secondary-to-radiation-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-anaemia-in-premature-babies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-atherothrombotic-events-after-an-acute-coronary-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-atherothrombotic-events-at-high-risk-of-ischaemic-events 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-atherothrombotic-events-in-patients-with-acute-coronary-syndrome-acs-or-a-history-of-myocardial-infarction-mi- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-atherothrombotic-events-in-symptomatic-peripheral-artery-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-blood-clots-after-heart-attack-or-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-cerebrovascular-spasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-clot-formation-during-haemodialysis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-deep-vein-thrombosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-dental-caries 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-diphtheria-tetanus-and-pertussis-in-infants-and-children-aged-6-weeks-through-6-years 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-diphtheria-tetanus-pertussis-and-poliomyelitis-in-children-6-weeks-through-6-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-herpes-zoster-shingles-in-adults-50-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-herpes-zoster-shingles-in-adults-aged-50-years-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-influenza-a-virus-a-h1n1-pdm09-a-h3n2-and-influenza-b-viruses 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-influenza-caused-by-virus-subtypes-a-and-b-contained-in-the-vaccine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-influenza-disease-caused-by-influenza-a-subtype-viruses-a-h1n1-a-h3n2-and-influenza-b-viruses-in-individuals-6-months-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-influenza-disease-caused-by-influenza-a-subtype-viruses-a-h1n1-a-h3n2-and-influenza-b-viruses-in-individuals-6-months-of-age-and-older-when-the-same-vaccine-virus-strains-are-circulating 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-influenza-disease-caused-by-influenza-a-subtype-viruses-a-h1n1-a-h3n2-and-influenza-b-viruses-in-people-6-months-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-influenza-disease-caused-by-influenza-a-subtype-viruses-a-h1n1-a-h3n2-and-influenza-b-viruses-in-people-6-months-of-age-and-older-when-the-circulating-influenza-a-and-b-viruses-are-expected-to-be-well-matched-to-the-vaccine-viruses- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-intraoperative-miosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-2-years-of-age-or-older-with-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-2-years-of-age-or-older-with-alcohol-use-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-2-years-of-age-or-older-with-cerebrospinal-fluid-leak 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-2-years-of-age-or-older-with-chronic-heart-disease-including-congestive-heart-failure-coronary-artery-disease-or-cardiac-transplantation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-2-years-of-age-or-older-with-chronic-lung-disease-including-chronic-obstructive-pulmonary-disease-copd-and-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-2-years-of-age-or-older-with-functional-or-anatomic-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-2-years-of-age-or-older-with-sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-in-adults-50-years-of-age-or-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-23f-and-33f-in-adults-18-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-alcohol-use-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-cerebrospinal-fluid-leaks 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-cerebrospinal-fluid-shunts 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-certain-underlying-medical-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-chronic-kidney-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-cochlear-implantation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-cochlear-implants 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-functional-or-anatomic-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-heart-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-immunocompromised-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-18-years-of-age-and-older-with-lung-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-alcohol-use-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-cerebrospinal-fluid-leaks 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-cerebrospinal-fluid-shunts 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-certain-underlying-medical-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-chronic-kidney-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-cochlear-implants 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-functional-or-anatomic-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-heart-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-immunocompromised-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-50-years-of-age-and-older-with-lung-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-alcohol-use-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-cerebrospinal-fluid-leaks 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-cerebrospinal-fluid-shunts 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-certain-underlying-medical-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-chronic-kidney-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-cochlear-implants 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-functional-or-anatomic-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-heart-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-immunocompromised-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-disease-caused-by-streptococcus-pneumoniae-serotypes-1-3-4-5-6b-7f-9v-14-18c-19a-19f-22f-and-23f-in-adults-65-years-of-age-and-older-with-lung-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-and-pneumococcal-pneumonia-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection-and-cerebrospinal-fluid-leak-and-cochlear-implant-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection-and-sickle-cell-disease-and-cerebrospinal-fluid-leak-and-cochlear-implant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection-and-sickle-cell-disease-and-cerebrospinal-fluid-leak-and-cochlear-implant-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection-and-sickle-cell-disease-and-cerebrospinal-fluid-leak-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection-and-sickle-cell-disease-and-cochlear-implant-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-cerebrospinal-fluid-leak 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-cerebrospinal-fluid-leak-and-cochlear-implant-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-cerebrospinal-fluid-leak-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-certain-underlying-medical-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-chronic-heart-disease-chronic-lung-disease-diabetes-mellitus-or-alcoholism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-cochlear-implant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-cochlear-implant-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-functional-or-anatomic-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-immunocompromising-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-hiv-infection-and-cerebrospinal-fluid-leak 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-hiv-infection-and-cochlear-implant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-hiv-infection-and-sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-cerebrospinal-fluid-leak 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-cerebrospinal-fluid-leak-and-cochlear-implant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-cochlear-implant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-sickle-cell-disease-and-cerebrospinal-fluid-leak 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease-and-sickle-cell-disease-and-cochlear-implant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-sickle-cell-disease-and-cerebrospinal-fluid-leak-and-cochlear-implant-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-sickle-cell-disease-and-other-conditions-that-increase-the-risk-of-invasive-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-50-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-ipd-caused-by-streptococcus-pneumoniae-in-adults-65-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-hiv-infection- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-alcohol-use-disorder- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-cerebrospinal-fluid-leak- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-certain-underlying-medical-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-chronic-heart-disease- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-chronic-kidney-disease- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-chronic-liver-disease- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-chronic-lung-disease- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-cochlear-implant- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-diabetes- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-functional-or-anatomic-asplenia- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-other-conditions-that-compromise-the-immune-system- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older-with-sickle-cell-disease- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-18-years-of-age-and-older- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-caused-by-15-serotypes-of-streptococcus-pneumoniae-in-adults-50-years-of-age-and-older- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-invasive-pneumococcal-disease-in-adults-18- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-migraine-attacks 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-migraine-attacks-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-migraine-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-opioid-abuse 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-ovarian-hyperstimulation-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-pneumococcal-meningitis-in-children-2-years-of-age-or-older-with-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-pneumococcal-meningitis-in-children-2-years-of-age-or-older-with-functional-or-anatomic-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-pneumococcal-pneumonia-in-adults-18- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-postmenopausal-osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-premature-ovulation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-premature-ovulation-during-controlled-ovarian-stimulation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-pulmonary-embolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-rabies-in-individuals-who-have-been-bitten-or-otherwise-exposed-to-rabies-or-have-been-at-risk-of-rabies-exposure-and-have-been-vaccinated-with-a-cell-culture-vaccine-or-an-inactivated-rabies-vaccine- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-recurrence-of-ischemic-cerebrovascular-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-respiratory-syncytial-virus-rsv-disease-in-adults-aged-60-years-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-severe-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virus-rsv-in-infants-with-a-high-risk-of-rsv-disease-due-to-certain-chronic-lung-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-severe-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virus-rsv-in-infants-with-a-high-risk-of-rsv-disease-due-to-certain-heart-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-severe-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virus-rsv-in-infants-with-a-high-risk-of-rsv-disease-due-to-prematurity- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-severe-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virus-rsv-in-infants-with-a-high-risk-of-rsv-associated-hospitalization-due-to-prematurity- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-severe-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virus-rsv-in-young-children-with-a-history-of-premature-birth-or-bronchopulmonary-dysplasia- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-stroke-caused-by-a-clot-in-a-blood-vessel-in-the-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-systemic-embolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-systemic-embolism-caused-by-a-clot-in-a-blood-vessel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-venous-thromboembolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-venous-thromboembolism-from-re-occuring 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-venous-thromboembolism-in-undergoing-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preventive-treatment-of-episodic-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preventive-treatment-of-episodic-migraine-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/preventive-treatment-of-menstrual-migraine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevotella-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevotella-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevotella-postpartum-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevotella-septic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-closed-angle-glaucoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-dysbetalipoproteinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hyperlipidemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hypogonadism-due-to-bilateral-torsion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hypogonadism-due-to-orchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-immunodeficiency-pi- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-immunoglobulin-a-nephropathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-prevention-of-coronary-heart-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-adrenocortical-insufficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-biliary-cirrhosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-cholangitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-cutaneous-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-genital-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hemophagocytic-lymphohistiocytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hyperoxaluria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hyperoxaluria-type-i 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hypogonadism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hypothyroidism-replacement-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-malignant-neoplasm-of-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-malignant-neoplasm-of-gastrointestinal-tract 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-myelofibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-ovarian-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-progressive-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prinzmetal-angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pro-opiomelanocortin-pomc-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/processingdeficient-progeroid-laminopathies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proctitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/progressive-diffuse-large-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/progressive-pulmonary-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/progressive-myositis-ossificans 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proliferating-infantile-haemangioma-requiring-systemic-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prolonged-severe-nausea-and-vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-and-therapy-of-hemorrhagic-disease-of-the-newborn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-congenital-toxoplasmosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-deep-vein-thrombosis-in-medical-patients-with-severely-restricted-mobility-during-acute-illness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-deep-vein-thrombosis-in-patients-undergoing-abdominal-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-deep-vein-thrombosis-in-patients-undergoing-hip-replacement-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-hemorrhagic-disease-of-the-newborn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-ischemic-complications-in-non-q-wave-myocardial-infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-ischemic-complications-in-unstable-angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-primary-or-recurrent-stage-ta-and-or-t1-papillary-tumors-following-transurethral-resection-tur- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-repetitive-paroxysmal-supraventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prophylaxis-of-stage-tag1-papillary-tumors-at-high-risk-of-tumor-recurrence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prostate-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/prostate-cancer-prevention-age-manipulation- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prostatic-carcinoma-palliative-therapy-of-advanced-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prosthetic-arthroplasty-infection-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prosthetic-heart-valve-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/protection-against-diphtheria-tetanus-pertussis-whole-cell-hepatitis-b-poliomyelitis-inactivated-and-haemophilus-influenzae-type-b-hib-disease-in-infants-and-children-from-6-weeks-through-6-years-of-age-when-used-in-a-3-dose-series- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/protection-against-diphtheria-tetanus-pertussis-whole-cell-hepatitis-b-poliomyelitis-inactivated-and-haemophilus-influenzae-type-b-hib-disease-in-infants-and-children-from-6-weeks-through-6-years-of-age- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/protein-losing-enteropathy-secondary-to-single-ventricle 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-mirabilis-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-prostatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-pyelonephritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/proteus-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/providencia-complicated-uti 2026-04-19 weekly 0.8 https://druglandscape.com/disease/providencia-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/providencia-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prurigo-nodularis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pruritus-ani 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pruritus-associated-with-atopic-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pruritus-associated-with-chronic-kidney-disease-ckd-ap- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pruritus-in-progressive-familial-intrahepatic-cholestasis-pfic- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pruritus-of-genital-organs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudobulbar-affect 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomembranous-enterocolitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-biliary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-complicated-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-aeruginosa-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-respiratory-tract-infection-in-cystic-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-gastrointestinal-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pseudomonas-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psoriasis-vulgaris 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psoriasis-with-arthropathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psoriatic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psoriatic-arthritis-psa- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psoriatic-arthritis-and-ankylosing-spondylitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psoriatic-arthritis-with-distal-interphalangeal-involvement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/psychotic-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-arterial-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-edema-due-to-chronic-heart-failure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-mycobacterium-avium-complex-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-thromboembolism-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-actinomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-artery-stenosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-cryptococcosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-embolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-emphysema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-lymphangioleiomyomatosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-thromboembolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/punctate-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/punctate-keratopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pustular-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pyelonephritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pyoderma-gangrenosum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pyridoxine-dependent-seizure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pyrimethamine-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pyruvate-kinase-pk-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/q-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/q-fever-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/quartan-malaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rabies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rabies-booster- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rabies-post-exposure- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rabies-pre-exposure- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/radioactive-cesium-decontamination 2026-04-19 weekly 0.8 https://druglandscape.com/disease/radiographic-imaging-procedure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/radiolabelling-of-carrier-molecules 2026-04-19 weekly 0.8 https://druglandscape.com/disease/radionuclide-myocardial-perfusion-study 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rat-bite-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/raynaud-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reactive-oxygen-species-1-positive-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rectal-chlamydia-trachomatis-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rectal-cancer-with-wild-type-ras 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rectal-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-calcium-renal-calculi 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-mucocutaneous-herpes-simplex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-mucocutaneous-herpes-simplex-in-human-immunodeficiency-virus-infected-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-persistent-urethritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-chronic-lymphocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-genital-herpes-simplex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-herpes-simplex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-herpes-simplex-labialis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-or-metastatic-non-keratinizing-nasopharyngeal-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-or-advanced-endometrial-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-or-metastatic-cervical-cancer-with-disease-progression-on-or-after-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-vulvovaginal-candidiasis-rvvc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/red-eye 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduce-need-for-replacement-therapy-in-hemophilia-patients-during-tooth-extraction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduce-need-for-replacement-therapy-in-hemophilia-patients-following-tooth-extraction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduce-or-prevent-hemorrhage-in-hemophilia-patients-during-tooth-extraction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduce-or-prevent-hemorrhage-in-hemophilia-patients-following-tooth-extraction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduce-the-risk-of-ototoxicity-associated-with-cisplatin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reducing-cardiovascular-mortality 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reducing-risk-of-developing-coronary-heart-disease-in-type-iib-patients-without-history-or-symptoms-of-existing-coronary-heart-disease-with-low-hdl-cholesterol-elevated-ldl-cholesterol-and-elevated-triglycerides-unresponsive-to-weight-loss-diet-exercise-and-other-pharmacologic-agents 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reducing-the-risk-of-fatal-and-nonfatal-cardiovascular-events 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reducing-the-risk-of-myocardial-infarctions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reducing-the-risk-of-stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduction-of-transmission-of-genital-herpes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduction-of-risk-of-upper-gastrointestinal-bleeding 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduction-of-sputum-viscosity-in-chronic-obstructive-pulmonary-disease-copd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reduction-of-thrombotic-cardiovascular-events-in-patients-with-atherosclerotic-disease-including-those-with-a-recent-ischemic-stroke-or-peripheral-artery-disease-pad- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-aspergillosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-acute-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-acute-myeloid-leukemia-with-a-susceptible-idh1-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-anemia-clinical- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-autoimmune-haemolytic-anaemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-chronic-cough 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-chronic-lymphocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-generalized-myasthenia-gravis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-idiopathic-thrombocytopenic-purpura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-peripheral-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/refractory-moderate-to-severe-atopic-dermatitis-in-adults-and-pediatric-patients-12-years-of-age-and-older-not-adequately-controlled-with-other-systemic-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/regional-anesthesia-for-labor-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/regional-anesthesia-for-ophthalmologic-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/regional-anesthesia-for-postoperative-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/regional-anesthesia-for-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapse-multiple-myeloma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-acute-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-adult-t-cell-leukemia-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-angioimmunoblastic-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-chronic-lymphocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-cutaneous-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-diffuse-large-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-graft-versus-host-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-hairy-cell-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-kaposi-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-mantle-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-marginal-zone-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-1-line-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-1-line-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-1-line-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-1-line-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-10-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-10-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-10-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-10-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-10-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-10-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-100-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-101-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-102-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-103-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-11-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-11-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-11-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-11-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-11-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-11-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-12-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-12-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-12-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-12-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-12-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-12-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-13-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-13-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-13-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-13-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-13-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-13-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-14-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-14-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-14-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-14-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-14-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-14-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-15-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-15-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-15-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-15-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-15-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-15-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-16-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-16-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-16-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-16-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-16-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-16-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-17-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-17-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-17-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-17-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-17-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-17-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-18-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-18-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-18-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-18-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-18-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-18-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-19-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-19-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-19-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-2-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-2-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-2-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-2-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-2-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-2-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-20-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-20-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-21-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-21-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-22-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-22-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-23-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-23-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-24-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-24-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-25-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-25-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-26-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-26-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-27-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-27-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-28-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-28-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-29-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-29-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-3-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-3-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-3-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-3-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-3-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-3-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-30-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-30-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-31-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-31-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-32-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-32-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-33-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-33-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-34-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-34-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-35-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-35-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-36-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-36-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-37-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-37-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-38-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-38-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-39-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-39-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-4-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-4-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-4-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-4-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-4-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-4-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-40-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-40-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-41-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-41-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-42-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-42-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-43-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-43-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-44-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-44-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-45-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-45-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-46-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-46-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-47-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-47-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-48-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-48-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-49-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-49-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-5-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-5-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-5-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-5-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-5-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-5-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-50-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-50-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-51-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-51-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-52-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-52-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-53-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-53-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-54-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-54-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-55-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-55-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-56-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-56-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-57-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-57-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-58-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-58-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-59-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-59-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-6-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-6-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-6-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-6-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-6-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-6-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-60-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-60-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-61-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-61-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-62-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-62-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-63-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-63-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-64-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-64-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-65-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-65-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-66-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-66-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-67-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-67-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-68-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-68-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-69-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-69-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-7-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-7-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-7-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-7-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-7-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-7-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-70-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-70-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-71-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-71-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-72-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-72-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-73-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-73-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-74-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-74-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-75-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-75-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-76-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-76-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-77-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-77-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-78-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-78-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-79-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-79-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-8-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-8-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-8-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-8-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-8-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-8-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-80-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-80-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-81-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-81-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-82-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-82-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-83-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-83-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-84-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-84-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-85-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-85-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-86-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-86-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-87-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-87-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-88-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-88-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-89-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-89-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-9-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-9-lines-of-therapy-and-a-proteasome-inhibitor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-9-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-9-lines-of-therapy-and-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-a-cd38-directed-monoclonal-antibody 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-9-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-9-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-90-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-90-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-91-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-91-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-92-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-92-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-93-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-93-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-94-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-94-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-95-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-95-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-96-prior-lines-of-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-96-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-97-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-98-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-after-at-least-99-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-mycosis-fungoides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-peripheral-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-post-transplant-lymphoproliferative-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-primary-mediastinal-large-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-s-zary-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-t-cell-large-granular-lymphocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-waldenstr-m-macroglobulinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-cd22-positive-b-cell-precursor-acute-lymphoblastic-leukemia-all-in-adult-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-cd22-positive-b-cell-precursor-acute-lymphoblastic-leukemia-all-in-pediatric-patients-1-year-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-t-cell-leukemia-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-advanced-follicular-lymphoma-fl-after-at-least-two-prior-lines-of-therapy-for-whom-mab-based-therapy-has-failed 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-after-at-least-two-prior-lines-of-therapy-for-whom-mab-based-therapy-has-failed 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl-after-at-least-two-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-follicular-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-follicular-lymphoma-after-at-least-two-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-mantle-cell-lymphoma-mcl-after-at-least-two-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-marginal-zone-lymphoma-mzl-after-at-least-two-prior-lines-of-therapy-for-whom-mab-based-therapy-has-failed 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-marginal-zone-lymphoma-mzl-after-at-least-two-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-multiple-myeloma-in-combination-with-dexamethasone-and-daratumumab-and-carfilzomib-and-isatuximab-and-elotuzumab-and-ixazomib-and-bortezomib-and-pomalidomide-and-lenalidomide-and-pf-06863135-and-bortezomib-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab-and-isatuximab-and-elotuzumab-and-ixazomib-and-carfilzomib-and-daratumumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-small-lymphocytic-lymphoma-sll-after-at-least-two-prior-therapies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-refractory-metastatic-breast-cancer-in-combination-with-vorinostat- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsing-acute-myeloid-leukemia-with-a-susceptible-idh1-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsing-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsing-forms-of-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsing-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsing-remitting-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relief-of-skeletal-muscle-spasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relief-of-symptoms-of-cough 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relief-of-symptoms-of-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relief-of-symptoms-of-runny-nose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/remission-of-prediabetes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/removal-of-escars-from-deep-thermal-burn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-cell-carcinoma-rcc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-disease-with-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-osteodystrophy-with-hyperphosphatemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-anemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-arteriography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-dialysis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-edema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-function-study 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-osteodystrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-radiation-exposure-from-lutetium-177lu-oxodotreotide 2026-04-19 weekly 0.8 https://druglandscape.com/disease/renal-transplant-rejection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/resistant-chronic-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/respiratory-cystic-fibrosis-with-pseudomonas-aeruginosa-colonization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/respiratory-syncytial-virus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/respiratory-syncytial-virus-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/respiratory-distress-syndrome-in-the-newborn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/respiratory-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/respiratory-tract-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/restless-legs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/retention-of-urine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/retinoblastoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/retinopathy-of-prematurity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/retrograde-cystourethrography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/retrograde-pyelogram 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rett-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reversal-of-neuromuscular-blockade 2026-04-19 weekly 0.8 https://druglandscape.com/disease/reverse-mydriasis-from-ophthalmic-adrenergic-or-anticholinergic-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rhabdomyosarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rheumatic-fever-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rheumatic-heart-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rheumatism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rheumatoid-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rheumatoid-arthritis-ra- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rheumatoid-arthritis-in-patient-at-high-ulcer-risk 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rhinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rhinocerebral-phycomycosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rhinoscleroma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rhytidectomy-of-glabellar-frown-lines 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rickets 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rickettsialpox 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rifampicin-resistant-tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/right-sided-staphylococcus-aureus-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rocky-mountain-spotted-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rosacea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rotavirus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/routine-prophylaxis-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-in-adult-and-pediatric-patients-12-years-of-age-and-older-with-hemophilia-a-congenital-factor-viii-deficiency-without-factor-viii-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/routine-prophylaxis-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-in-adult-and-pediatric-patients-12-years-of-age-and-older-with-hemophilia-b-congenital-factor-ix-deficiency-without-factor-ix-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/routine-vaccination-of-adolescents-11-through-12-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/routine-vaccination-of-adolescents-13-through-18-years-of-age-who-have-not-previously-completed-the-series 2026-04-19 weekly 0.8 https://druglandscape.com/disease/routine-vaccination-of-adults-19-through-26-years-of-age-who-have-not-previously-completed-the-series 2026-04-19 weekly 0.8 https://druglandscape.com/disease/routine-vaccination-of-adults-27-years-of-age-and-older-who-have-not-previously-completed-the-series 2026-04-19 weekly 0.8 https://druglandscape.com/disease/routine-vaccination-of-individuals-11-through-64-years-of-age-with-certain-risk-factors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/scid-due-to-absent-adenosine-deaminase 2026-04-19 weekly 0.8 https://druglandscape.com/disease/safety-and-efficacy-of-chlorthalidone-in-type-1-diabetes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/salmonella-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/salmonella-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/salpingitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sarcoidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sarcoma-of-soft-tissue 2026-04-19 weekly 0.8 https://druglandscape.com/disease/scalp-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/scarlet-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/scarring 2026-04-19 weekly 0.8 https://druglandscape.com/disease/schistosomiasis-due-to-s-haematobium 2026-04-19 weekly 0.8 https://druglandscape.com/disease/schistosomiasis-due-to-s-japonicum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/schistosomiasis-due-to-s-mansoni 2026-04-19 weekly 0.8 https://druglandscape.com/disease/schistosomiasis-due-to-s-mekongi 2026-04-19 weekly 0.8 https://druglandscape.com/disease/schizophrenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/screening-for-adrenocortical-insufficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/scrub-typhus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seasonal-affective-disorder-sad- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seasonal-affective-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seasonal-allergic-rhinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seasonal-colds 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seborrheic-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/second-line-treatment-of-metastatic-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondarily-generalized-seizures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-glaucoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-hyperparathyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-hypothyroidism-replacement-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-infection-of-erosion-and-ulcer-caused-by-mrsa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-infection-of-surgical-wounds-caused-by-mrsa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-infection-of-trauma-and-burn-wounds-caused-by-mrsa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-malignant-neoplasm-of-colon 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-malignant-neoplasm-of-female-breast 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-malignant-neoplasm-of-kidney 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-malignant-neoplasm-of-pancreas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-malignant-neoplasm-of-stomach 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-physiologic-amenorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-progressive-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-stroke-prevention-in-older-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secondary-syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/secretin-stimulation-testing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sedation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sedation-as-adjunct-to-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sedation-in-intubated-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sedation-of-intubated-and-mechanically-ventilated-adult-patients-in-an-intensive-care-unit-or-coronary-care-unit- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sedation-of-mechanically-ventilated-adult-patients-in-an-intensive-care-unit-or-coronary-care-unit- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sedation-of-non-intubated-patients-in-the-intensive-care-unit-icu-or-in-a-hospital-setting-receiving-mechanical-ventilation- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seizure-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seizures-associated-with-cdkl5-deficiency-disorders 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seizures-associated-with-dravet-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seizures-associated-with-amyotrophic-lateral-sclerosis-als- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/seizures-in-neurosurgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/senile-dementia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sentinel-lymph-node-mapping 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sentinel-lymph-node-mapping-in-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sentinel-lymph-node-mapping-in-malignant-melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-caused-by-haemophilus-influenzae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-caused-by-serratia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-caused-by-methicillin-resistant-staphylococcus-aureus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-due-to-gram-negative-bacteria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-due-to-pseudomonas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-due-to-staphylococcus-aureus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-due-to-streptococcus-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepsis-of-the-newborn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septic-abortion-due-to-porphyromonas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septicemia-due-to-bacteroides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septicemia-due-to-escherichia-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septicemia-due-to-serratia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septicemia-due-to-enterococcus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septicemia-due-to-fungus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septicemic-plague 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serratia-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serratia-complicated-uti 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serratia-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serratia-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serratia-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serratia-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serratia-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/serum-thyroglobulin-level 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-axillary-hyperhidrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-insomnia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-ocular-inflammation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-pain-with-opioid-tolerance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-pruritus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-recalcitrant-nodular-acne 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-recalcitrant-nodular-rosacea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-recalcitrant-psoriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-adrenal-insufficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-anxiety-panic- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-chronic-obstructive-pulmonary-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-growth-hormone-deficiency-in-adulthood 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-hereditary-factor-viii-deficiency-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-hypoglycaemia-in-patients-with-diabetes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-major-depression-with-psychotic-features 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-myoclonic-epilepsy-in-infancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-acute-hypotension-in-adult-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sexually-transmitted-epididymo-orchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/shigellosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-bowel-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-stature-associated-with-shox-deficiency-in-pediatric-patients-2-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-stature-associated-with-turner-syndrome-in-pediatric-patients-2-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-stature-associated-with-idiopathic-growth-hormone-deficiency-in-pediatric-patients-2-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-stature-associated-with-other-causes-of-growth-hormone-deficiency-in-pediatric-patients-2-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-term-management-of-acute-pain-severe-enough-to-require-an-opioid-analgesic-and-for-which-alternative-treatments-are-inadequate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-term-preoperative-treatment-of-primary-hyperaldosteronism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/short-term-relief-of-symptoms-of-anxiety 2026-04-19 weekly 0.8 https://druglandscape.com/disease/shoulder-tendonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sickling-disorder-due-to-hemoglobin-s 2026-04-19 weekly 0.8 https://druglandscape.com/disease/simple-goiter 2026-04-19 weekly 0.8 https://druglandscape.com/disease/simple-partial-seizure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sinus-bradycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sinus-node-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sinus-headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sinus-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sinusitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sitosterolemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sj-gren-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skeletal-muscle-relaxation-for-endotracheal-intubation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-grafting-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-pigmentation-enhancement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-acinetobacter-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-anaerobic-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-bacteroides-fragilis-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-citrobacter-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-clostridium-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-enterococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-fusobacterium-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-morganella-morganii-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-peptococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-proteus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-providencia-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-pseudomonas-aeruginosa-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-serratia-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-staphylococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-streptococcus-agalactiae-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-skin-structure-streptococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-and-soft-tissue-infections-due-to-susceptible-streptococci 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-toxicity-from-egfr-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-ulcer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sleepiness-due-to-obstructive-sleep-apnea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sleepiness-due-to-shift-work-sleep-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/slow-progression-of-coronary-artery-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/small-cell-lung-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/small-cell-carcinoma-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/small-intestine-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/small-cell-lung-cancer-olaparib-low-dose-radiotherapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/smoking-cessation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/smoking-cessation-assistance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/snake-bite-wound 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sneezing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/social-anxiety-disorder-sad- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/social-phobia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/soft-or-connective-tissue-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/solar-lentigines 2026-04-19 weekly 0.8 https://druglandscape.com/disease/solid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/solid-malignant-tumours 2026-04-19 weekly 0.8 https://druglandscape.com/disease/solid-neoplasm-with-neurotrophic-receptor-tyrosine-kinase-gene-fusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sore-throat-symptom 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spasm-of-cerebral-arteries 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spasticity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spasticity-caused-by-cerebral-palsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spinal-muscular-atrophy-sma-with-a-genetically-confirmed-diagnosis-of-sma-type-1-or-sma-type-2-or-3-in-patients-with-a-body-weight-of-13-kg-or-less 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spinal-muscular-atrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spinal-muscular-atrophy-with-two-copies-of-a-healthy-smn2-gene 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spinocerebellar-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/spironolactone-in-ckd-enabled-by-chlorthalidone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/splenomegaly 2026-04-19 weekly 0.8 https://druglandscape.com/disease/splenoportogram-by-splenic-arteriography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sporotrichosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sprains-and-strains 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-the-head-and-neck 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-the-head-and-neck-scchn-with-disease-progression-on-or-after-platinum-containing-chemotherapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-larynx 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-mouth 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-nose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-cell-carcinoma-of-pharynx 2026-04-19 weekly 0.8 https://druglandscape.com/disease/squamous-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staining-method 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staph-aureus-traumatic-skin-lesion-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-prosthetic-heart-valve-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-enterocolitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-infection-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-infectious-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-pharyngitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcal-tonsillitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-acute-otitis-media 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-aureus-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-aureus-complicated-uti 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-aureus-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-aureus-otitis-externa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-aureus-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-epidermidis-skin-and-skin-structure-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-epidermidis-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-lung-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-nosocomial-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/staphylococcus-saprophyticus-urinary-tract-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stargardt-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/status-epilepticus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stevens-johnson-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/still-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stimulated-gastric-secretory-test 2026-04-19 weekly 0.8 https://druglandscape.com/disease/strabismus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-endometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-endomyometritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-pelvic-cellulitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-pelvic-inflammatory-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-peritonitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-postpartum-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-septic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-infection-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-infectious-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-tonsillitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcal-toxic-shock-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-complicated-appendicitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-empyema 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-lung-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-myositis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pericarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-chronic-bronchitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-18-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-18-years-of-age-and-older-with-chronic-heart-disease-chronic-lung-disease-diabetes-mellitus-or-functional-or-anatomical-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-hiv-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-cerebrospinal-fluid-leak 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-cochlear-implant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-functional-or-anatomical-asplenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-immunocompromising-conditions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-other-conditions-that-put-them-at-increased-risk-for-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-other-health-conditions-that-put-them-at-increased-risk-for-pneumococcal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-19-through-64-years-of-age-with-sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-50-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-3-4-5-6a-6b-7f-9v-14-18c-19a-19f-and-23f-in-adults-65-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-1-4-5-6b-7f-9v-14-18c-19f-and-23f-in-children-6-through-17-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pneumoniae-serotypes-4-6b-9v-14-18c-19f-and-23f-in-children-2-through-5-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/streptococcus-pyogenes-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stress-echocardiography-using-dobutamine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/striatal-dopamine-transporter-visualization-using-single-photon-emission-computed-tomography 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stroke 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stroke-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/struvite-renal-calculi 2026-04-19 weekly 0.8 https://druglandscape.com/disease/subacute-stent-thrombosis-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/subacute-bursitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/subarachnoid-intracranial-hemorrhage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/subcutaneous-fluid-administration-for-achieving-hydration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/subcutaneous-clysis-of-patient-for-fluid-administration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/subcutaneous-nitroglycerin-to-facilitate-trans-radial-access 2026-04-19 weekly 0.8 https://druglandscape.com/disease/subependymal-giant-cell-astrocytoma-associated-with-tuberous-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sucrase-isomaltase-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suicidal-behavior-in-schizoaffective-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suicidal-behavior-in-schizophrenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sulfadiazine-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sunscreen-agent 2026-04-19 weekly 0.8 https://druglandscape.com/disease/superficial-benign-epitheliomatosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/superficial-ocular-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/superficial-bacterial-infection-of-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/superficial-basal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/supplementation-of-nitrous-oxide-in-oxygen-during-maintenance-of-anesthesia-for-cervical-conization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/supplementation-of-nitrous-oxide-in-oxygen-during-maintenance-of-anesthesia-for-dilation-and-curettage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/supplementation-of-subpotent-anesthetic-agents-during-maintenance-of-anesthesia-for-short-operative-procedures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/support-of-pincer-nail-correction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suppression-of-genital-herpes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suppression-of-recurrent-herpes-simplex-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suppression-of-recurrent-herpes-simplex-infection-in-hiv 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suppression-of-recurrence-of-malignant-pleural-effusions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suppression-of-the-gag-reflex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suprapubic-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/supraventricular-arrhythmia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/supraventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/surgical-hemostasis-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/surgical-hand-scrub 2026-04-19 weekly 0.8 https://druglandscape.com/disease/surgical-procedure-on-eye-proper 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sustained-ventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sympathetic-uveitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/symptomatic-relief-of-acute-alcohol-withdrawal 2026-04-19 weekly 0.8 https://druglandscape.com/disease/syncope-due-to-heart-block 2026-04-19 weekly 0.8 https://druglandscape.com/disease/syndrome-of-inappropriate-vasopressin-secretion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-bacterial-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-candida-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-citrobacter-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-cryptococcal-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-enterobacter-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-escherichia-coli-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-group-b-streptococcal-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-klebsiella-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-neonatal-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-nosocomial-pneumonia-due-to-pseudomonas-aeruginosa 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-p-aeruginosa-infection-in-cystic-fibrosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-proteus-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-pseudomonas-aeruginosa-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-pseudomonas-aeruginosa-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-pseudomonas-aeruginosa-osteomyelitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-pseudomonas-aeruginosa-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-pseudomonas-aeruginosa-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-serratia-meningitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-skin-and-skin-structure-pseudomonas-aeruginosa-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-staphylococcal-endocarditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-staphylococcal-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-staphylococcal-joint-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-staphylococcal-septicemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-staphylococcus-aureus-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synergy-for-staphylococcus-skin-and-skin-structure-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synovitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synovitis-e-g-of-the-knee-elbow- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/synovitis-due-to-osteoarthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/syphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/syphilis-excluding-neurosyphilis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-al-amyloidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-candidiasis-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-cryptococcosis-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-dermatomyositis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-juvenile-idiopathic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-lupus-erythematosus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-mast-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-onset-juvenile-chronic-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/systemic-sclerosis-associated-interstitial-lung-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/t-cell-acute-lymphoblastic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/t3-suppression-for-thyroid-function-test 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tb-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tb-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tnf-receptor-associated-periodic-fever-syndrome-traps- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tsh-suppression-in-thyrotropin-dependent-well-differentiated-thyroid-cancer-adjunct-to-radioiodine-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tsh-suppression-in-thyrotropin-dependent-well-differentiated-thyroid-cancer-adjunct-to-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tachyarrhythmia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tardive-dyskinesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tear-film-insufficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-constipation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-diarrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-dizziness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-dry-itchy-or-cracked-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-exhaustion-or-weakness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-minor-joint-pain-or-stiffness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/temporary-relief-of-muscle-soreness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tendinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tendinitis-e-g-achilles-rotator-cuff- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tendinosis-e-g-patellar- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tenosynovial-giant-cell-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tenosynovitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tension-type-headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tertiary-bejel 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tertiary-hypothyroidism-replacement-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tertiary-lesion-of-yaws 2026-04-19 weekly 0.8 https://druglandscape.com/disease/testicular-germ-cell-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-adjunct-treatment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-diphtheria-and-pertussis-tdap- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-diphtheria-and-pertussis-tdap-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-diphtheria-and-pertussis-tdap-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-diphtheria-and-pertussis-tdap-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-diphtheria-and-pertussis-tdap-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-diphtheria-and-pertussis-tdap-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetanus-diphtheria-and-pertussis-toxoids-adsorbed-tdap-booster-dose-in-individuals-11-through-64-years-of-age 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetany 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetrahydrobiopterin-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tetralogy-of-fallot 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thallium-poisoning 2026-04-19 weekly 0.8 https://druglandscape.com/disease/the-suppression-of-graft-versus-host-disease-in-hematopoietic-stem-cell-transplantation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/therapeutic-abortion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/therapeutic-opioid-induced-constipation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/therapy-of-hemorrhagic-disease-of-the-newborn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thiamin-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thick-bronchial-secretions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thromboangiitis-obliterans 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thrombocytopenic-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thrombocytosis-in-myeloproliferative-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thromboembolic-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thromboembolic-pulmonary-hypertension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thromboembolism-due-to-prosthetic-heart-valves 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thrombosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thrombosis-prevention-in-heparin-induced-thrombocytopenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thrombosis-in-heparin-induced-thrombocytopenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thrombotic-thrombocytopenic-purpura 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thymic-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thyroid-cancer 2026-03-25 weekly 0.8 https://druglandscape.com/disease/thyroid-gland-radiation-protection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thyroid-suppression-test 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thyroid-eye-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thyroid-stimulating-hormone-secreting-pituitary-tumour 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thyroiditis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thyrotoxic-crisis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tinea-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tinea-barbae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tinea-capitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tinea-corporis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tinea-cruris 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tinea-pedis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/to-reduce-the-development-of-drug-resistant-bacteria-and-maintain-the-effectiveness-of-zithromax-and-other-antibacterial-drugs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tobacco-dependence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tobacco-use-cessation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tobacco-use-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tonic-clonic-epilepsy-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tonic-clonic-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tonic-clonic-seizure 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tonic-clonic-seizure-in-patients-with-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tonsillitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tonsillitis-due-to-haemophilus-influenzae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tonsillitis-due-to-streptococcus-pyogenes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/topical-local-anesthetic-to-eye 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toxic-damage-from-alcohol-or-heavy-metals 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toxic-effect-of-arsenic-and-or-its-compounds 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toxic-effect-of-cyanide 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toxic-plasma-methotrexate-concentration-reduction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toxicodendron-radicans 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toxoplasmosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toxoplasmosis-associated-with-acquired-immunodeficiency-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/trachoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transfusion-reaction-urticaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transfusion-reaction-due-to-serum-protein-reaction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transitional-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transplant-of-kidney 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transplanted-organ-rejection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transthyretin-ttr-amyloid-cardiomyopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transthyretin-amyloid-cardiomyopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transthyretin-familial-amyloid-polyneuropathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transthyretin-related-familial-amyloid-cardiomyopathy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/transurethral-prostatectomy-infection-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/traumatic-skin-lesion-streptococcus-pyogenes-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/traveler-s-diarrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-refractory-type-2-diabetes-mellitus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-and-prophylaxis-of-carcinoma-in-situ-cis-of-the-urinary-bladder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-myeloid-leukemia-aml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-aggressive-systemic-mastocytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-covid-19-in-adults-and-pediatric-patients-12-years-of-age-and-older-who-are-at-high-risk-of-progression-to-severe-covid-19-including-those-who-are-hospitalized-due-to-covid-19-or-who-have-mild-to-moderate-covid-19-with-at-least-one-risk-factor-for-progression-to-severe-covid-19-e-g-older-age-certain-chronic-medical-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-chronic-myeloid-leukemia-cml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-essential-thrombocythemia-et- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-her2-positive-breast-cancer-in-patients-for-whom-trastuzumab-and-pertuzumab-are-indicated 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-her2-positive-breast-cancer-in-patients-who-have-received-prior-trastuzumab-based-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-her2-positive-unresectable-or-metastatic-breast-cancer-in-patients-who-have-received-prior-anti-her2-based-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hiv-1-infection-in-adults-and-pediatric-patients-3-months-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hiv-1-infection-in-adults-and-pediatric-patients-3-months-of-age-and-older-without-antiretroviral-treatment-options 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hiv-1-infection-in-adults-and-pediatric-patients-3-months-of-age-and-older-without-antiretroviral-treatment-options-or-for-whom-it-is-not-feasible-to-use-antiretroviral-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hiv-1-infection-in-adults-and-pediatric-patients-3-months-of-age-and-older-without-antiretroviral-treatment-options-or-for-whom-it-is-not-feasible-to-use-antiretroviral-therapy-in-certain-resource-limited-settings 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hiv-associated-wasting-in-adults- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hypereosinophilic-syndrome-hes- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-influenza 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-major-depressive-disorder-mdd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-mast-cell-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-mast-cell-sarcoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-mastocytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-mastocytosis-with-an-associated-hematological-neoplasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-mastocytosis-with-an-associated-neoplasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-mastocytosis-with-an-associated-non-hematological-neoplasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-myeloproliferative-neoplasms-mpns- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-polycythemia-vera-pv- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-prader-willi-syndrome-in-adults- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-primary-myelofibrosis-pmf- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-systemic-mastocytosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-turner-syndrome-in-adults- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-and-chronic-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-bacterial-exacerbation-of-chronic-bronchitis-abecb-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-bacterial-exacerbation-of-chronic-bronchitis-abecb-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-bacterial-exacerbation-of-chronic-obstructive-pulmonary-disease-abecopd-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-bacterial-exacerbation-of-chronic-obstructive-pulmonary-disease-abecopd-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-bacterial-sinusitis-abs-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-bacterial-sinusitis-abs-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-pyelonephritis-apn-caused-by-escherichia-coli-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-pyelonephritis-apn-caused-by-escherichia-coli- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-pyelonephritis-apn-caused-by-klebsiella-pneumoniae-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-pyelonephritis-apn-caused-by-klebsiella-pneumoniae- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-uncomplicated-influenza 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-acute-uncomplicated-plasmodium-falciparum-malaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-and-pediatric-patients-1-year-of-age-and-older-with-neurofibromatosis-type-1-nf1- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-and-pediatric-patients-1-year-of-age-and-older-with-neurofibromatosis-type-1-nf1-who-have-symptomatic-inoperable-plexiform-neurofibromas-pn- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-and-pediatric-patients-2-years-of-age-and-older-with-confirmed-fabry-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-are-not-eligible-for-or-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor-and-have-received-at-least-one-prior-therapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-failed-a-b-cell-receptor-bcr-pathway-inhibitor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion-and-have-received-at-least-one-prior-therapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-a-17p-deletion- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-cll-who-have-received-at-least-one-prior-therapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-type-iv-hyperlipidemia-with-very-high-serum-triglyceride-elevations-2-000-mg-dl-presenting-risk-of-pancreatitis-unresponsive-to-diet 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-type-v-hyperlipidemia-with-very-high-serum-triglyceride-elevations-2-000-mg-dl-presenting-risk-of-pancreatitis-unresponsive-to-diet 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-endocrine-resistant-pik3ca-mutated-hr-positive-her2-negative-locally-advanced-or-metastatic-breast-cancer-as-detected-by-an-fda-approved-test-following-recurrence-on-or-after-completing-adjuvant-endocrine-therapy-in-combination-with-inavolisib-and-fulvestrant 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-hormone-receptor-hr-positive-human-epidermal-growth-factor-receptor-2-her2-negative-advanced-or-metastatic-breast-cancer-in-combination-with-an-aromatase-inhibitor-as-initial-endocrine-based-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-hormone-receptor-hr-positive-human-epidermal-growth-factor-receptor-2-her2-negative-advanced-or-metastatic-breast-cancer-in-combination-with-fulvestrant-in-patients-with-disease-progression-following-endocrine-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-locally-advanced-unresectable-stage-iii-nsclc-whose-disease-has-not-progressed-during-or-following-concurrent-or-sequential-platinum-based-chemoradiation-therapy-and-whose-tumors-have-egfr-exon-19-deletions-or-exon-21-l858r-mutations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-metastatic-egfr-t790m-mutation-positive-nsclc-as-detected-by-an-fda-approved-test-whose-disease-has-progressed-on-or-after-egfr-tki-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-non-small-cell-lung-cancer-nsclc-harboring-an-egfr-exon-20-insertion-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-recurrent-or-metastatic-cervical-cancer-with-disease-progression-on-or-after-chemotherapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll-after-at-least-two-prior-therapies- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-severe-hemophilia-a-with-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-patients-with-triglyceride-elevations-between-1-000-2-000-mg-dl-and-history-of-pancreatitis-or-recurrent-abdominal-pain-typical-of-pancreatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-smokers-to-help-them-stop-smoking 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-smokers-with-a-history-of-serious-psychiatric-illness-to-help-them-stop-smoking 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-adult-onset-growth-hormone-deficiency- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-advanced-breast-cancer-in-postmenopausal-women-with-hormone-receptor-positive-or-hormone-receptor-negative-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-bladder-cancer-superficial- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-breast-cancer-in-postmenopausal-women-with-hormone-receptor-positive-or-hormone-receptor-negative-advanced-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-bronchial-asthma-transient-or-intermittent-in-nature-when-oral-therapy-is-not-appropriate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-bronchospasm-occurring-during-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-carcinoma-in-situ-cis-of-the-urinary-bladder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-central-precocious-puberty-cpp-gonadotropin-dependent-precocious-puberty-in-children-of-both-sexes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-burkitt-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-hodgkin-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-waldenstr-m-macroglobulinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-acute-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-adult-t-cell-leukemia-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-anaplastic-large-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-angioimmunoblastic-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-biliary-tract-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-cervical-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-chronic-lymphocytic-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-chronic-myeloid-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-cutaneous-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-diffuse-large-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-endometrial-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-fallopian-tube-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-follicular-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-gastric-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-head-and-neck-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-hepatocellular-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-mantle-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-marginal-zone-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-mast-cell-leukemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-multiple-myeloma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-myelodysplastic-syndromes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-myeloproliferative-neoplasms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-non-small-cell-lung-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-ovarian-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-pancreatic-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-peripheral-t-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-primary-peritoneal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-renal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-certain-types-of-thyroid-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-chronic-pain-associated-with-adult-patients-with-multiple-sclerosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-adrenal-gland 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-bone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-heart 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-kidney 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-adrenal-gland 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-anus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-bladder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-bone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-brain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-cervix 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-colon 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-heart 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-kidney 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-ovary 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-pancreas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-prostate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-rectum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-small-intestine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-stomach 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-testes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-thyroid-gland 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-uterus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-liver-and-the-vagina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-lung 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-ovary 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-pancreas 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-peritoneum 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-small-intestine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-stomach 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-colorectal-cancer-that-has-spread-to-the-thyroid-gland 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-community-acquired-pneumonia-cap-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-community-acquired-pneumonia-cap-caused-by-haemophilus-influenzae-haemophilus-parainfluenzae-or-moraxella-catarrhalis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-epilepsy-in-patients-with-a-history-of-status-epilepticus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-fibromyalgia-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-follicular-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-gastroesophageal-reflux-disease-gerd-in-patients-who-have-not-responded-adequately-to-proton-pump-inhibitor-ppi-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-generalized-anxiety-disorder-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-growth-hormone-deficiency-in-adults-with-a-history-of-pituitary-surgery- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-growth-hormone-deficiency-in-adults-with-a-history-of-radiation-therapy-to-the-head- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-growth-hormone-deficiency-in-adults- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-high-grade-non-muscle-invasive-bladder-cancer-nmibc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-high-risk-non-muscle-invasive-bladder-cancer-nmibc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hormone-receptor-positive-or-hormone-receptor-negative-breast-cancer-in-postmenopausal-women-with-advanced-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-hypotension-associated-with-anesthesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-insomnia-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-major-depressive-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-major-depressive-disorder-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-metastatic-colorectal-cancer-mcrc-in-combination-with-fluorouracil-and-leucovorin-in-patients-who-have-failed-or-are-intolerant-to-irinotecan-oxaliplatin-or-a-fluoropyrimidine- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-metastatic-colorectal-cancer-mcrc-in-combination-with-fluorouracil-and-leucovorin-in-patients-who-have-failed-oxaliplatin-based-chemotherapy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-metastatic-colorectal-cancer-mcrc-in-combination-with-fluorouracil-and-leucovorin- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-migraine-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-mild-to-moderate-covid-19-in-adults-and-pediatric-patients-5-years-of-age-and-older-who-weigh-at-least-40-kg- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-moderate-to-severe-symptoms-of-vulvar-and-vaginal-atrophy-associated-with-the-menopause 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause-and-prevention-of-postmenopausal-osteoporosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-the-menopause 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-neuropathic-pain-associated-with-diabetic-peripheral-neuropathy-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-non-muscle-invasive-bladder-cancer-nmibc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-cis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-partial-onset-seizures-with-and-without-secondary-generalization-in-patients-12-years-of-age-and-older-with-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-post-traumatic-stress-disorder-ptsd-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-postherpetic-neuralgia-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-cushing-s-syndrome- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-diarrhea- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-gastrointestinal-disorders- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hyperaldosteronism- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hyperparathyroidism- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hyperthyroidism- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-medications- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-other-causes- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-other-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-other-factors- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-other-health-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-other-medical-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-other-reasons- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-hypokalemia-due-to-other-underlying-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-impaired-renal-function- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-nasogastric-suction- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-normal-renal-function- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-potassium-loss-due-to-medications- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-potassium-loss-due-to-other-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-potassium-wasting-conditions- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-potassium-wasting-nephropathy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-potassium-wasting-renal-tubular-acidosis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-primary-aldosteronism- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-potassium-deficiency-hypokalemia-in-patients-with-vomiting- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-primary-generalized-tonic-clonic-seizures-in-patients-2-years-of-age-and-older-with-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-scchn-in-combination-with-5-fluorouracil- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-relapsing-forms-of-multiple-sclerosis-ms-to-reduce-the-frequency-of-clinical-exacerbations-and-to-delay-the-accumulation-of-physical-disability- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-seizures-associated-with-lennox-gastaut-syndrome-in-patients-2-years-of-age-and-older-with-epilepsy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-short-bowel-syndrome-and-failure-to-thrive-in-adults- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-sickle-cell-disease-scd-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-sickle-cell-disease-scd-in-pediatric-patients-4-years-of-age-and-older 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-superficial-bladder-cancer-stage-ta-t1-tis-high-grade-high-risk-carcinoma-in-situ-high-grade-tumor-high-risk-tumor-non-muscle-invasive-non-muscle-invasive-bladder-cancer-non-muscle-invasive-bladder-cancer-nmibc-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-risk-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor-non-muscle-invasive-bladder-cancer-nmibc-with-high-grade-tumor- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-symptomatic-venous-thromboembolism-to-reduce-recurrence-in-pediatric-patients-from-birth-gestational-age-at-least-35-weeks- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-treatment-resistant-depression-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-type-2-diabetes-mellitus-as-an-adjunct-to-diet-and-exercise-to-improve-glycemic-control-in-adults-with-type-2-diabetes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-cystitis-caused-by-escherichia-coli-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-cystitis-caused-by-escherichia-coli- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-cystitis-caused-by-klebsiella-pneumoniae-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-cystitis-caused-by-klebsiella-pneumoniae- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-urinary-tract-infections-utis-caused-by-escherichia-coli-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-urinary-tract-infections-utis-caused-by-escherichia-coli- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-urinary-tract-infections-utis-caused-by-klebsiella-pneumoniae-in-patients-who-have-a-penicillin-tolerance-test-result-of-20-mcg-ml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-uncomplicated-urinary-tract-infections-utis-caused-by-klebsiella-pneumoniae- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-of-unresectable-or-metastatic-colorectal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-prior-to-tumor-specific-t-cell-infusion-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-resistant-schizophrenia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/trichuriasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/trigeminal-neuralgia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/trigger-finger 2026-04-19 weekly 0.8 https://druglandscape.com/disease/trimethoprim-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/trimetrexate-toxicity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/triple-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/triple-negative-breast-neoplasms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/triple-negative-breast-cancer-tnbc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/triple-negative-breast-cancer-tnbc-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/triple-negative-breast-cancer-tnbc-in-adults-in-combination-with-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/triple-negative-breast-cancer-with-disease-progression-on-or-after-chemotherapy-in-the-neoadjuvant-or-adjuvant-setting-and-or-in-patients-with-measurable-disease-by-recist-v1-1 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tuberculosis-meningitis-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tuberculosis-of-meninges 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tuberous-sclerosis-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tubo-ovarian-abscess 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tularemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/turner-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/type-1-diabetes-mellitus-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/type-1-gaucher-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/type-2-diabetes 2026-03-25 weekly 0.8 https://druglandscape.com/disease/type-2-diabetes-mellitus-treatment-adjunct 2026-04-19 weekly 0.8 https://druglandscape.com/disease/type-2-diabetes-mellitus-with-multiple-risk-factors-for-chd 2026-04-19 weekly 0.8 https://druglandscape.com/disease/type-2-diabetes-mellitus-in-obese 2026-04-19 weekly 0.8 https://druglandscape.com/disease/typhoid 2026-04-19 weekly 0.8 https://druglandscape.com/disease/typhoid-injectable- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/typhoid-oral- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/typhoid-fever 2026-04-19 weekly 0.8 https://druglandscape.com/disease/typhus-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tyrosinemia-type-i 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ulcer-of-esophagus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ulcerated-haemangioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ulcerative-colitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ulcerative-colitis-uc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ulcerative-colitis-in-remission 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ulcerative-cystitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uncomplicated-skin-and-skin-structure-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uncomplicated-urinary-tract-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uncomplicated-urinary-tract-infections-cystitis- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uncomplicated-urogenital-gonorrhea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/undescended-testicle 2026-04-19 weekly 0.8 https://druglandscape.com/disease/undisclosed-indication-phase-1-terminated- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unknown-indication 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-advanced-or-recurrent-esophageal-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-advanced-or-recurrent-malignant-pleural-mesothelioma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-with-fgfr2-fusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-malignant-melanoma-with-braf-gene-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-hr-positive-her2-negative-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-adenocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-esophageal-squamous-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-esophageal-squamous-cell-carcinoma-escc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-melanoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-solid-tumors-with-braf-v600e-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-urothelial-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-advanced-or-recurrent-gastric-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unstable-crescendo-pre-infarction-angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unstable-angina-pectoris-during-ptca 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unstable-angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/untreated-hairy-cell-leukemia-with-active-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-gi-bleed-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-respiratory-infection-due-to-neisseria-meningitidis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-respiratory-pneumococcal-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-respiratory-streptococcal-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-gastrointestinal-hemorrhage 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-limb-spasticity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-limb-spasticity-in-pediatric-patients 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upper-respiratory-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/upset-stomach 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ureaplasma-urealyticum-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urethral-atrophy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urethritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urethritis-due-to-chlamydia-trachomatis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urge-incontinence-of-urine 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urge-urinary-incontinence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urgent-desire-to-urinate 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uric-acid-nephropathy-gout 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uric-acid-renal-calculus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-incontinence-due-to-detrusor-overactivity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-tract-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-bladder-stone 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-frequency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-incontinence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-tract-infection-caused-by-klebsiella 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-tract-infectious-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urinary-tract-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-cancer-bcg-unresponsive- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-cancer-mibc-neoadjuvant- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-cancer-platinum-ineligible- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-carcinoma-uc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-carcinoma-uc-in-adults 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-carcinoma-uc-in-adults-in-combination-with-pembrolizumab 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urothelial-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/urticaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/use-in-patients-for-whom-alternative-treatment-options-have-not-been-tolerated-or-are-not-expected-to-be-tolerated 2026-04-19 weekly 0.8 https://druglandscape.com/disease/use-in-patients-for-whom-alternative-treatment-options-have-not-provided-adequate-analgesia-or-are-not-expected-to-provide-adequate-analgesia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uterine-fibroids 2026-04-19 weekly 0.8 https://druglandscape.com/disease/uveitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vagal-reflex-bradycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vaginal-cuff-surgery-post-op-bacteroides-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vaginal-cuff-surgery-post-op-clostridium-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vaginal-cuff-surgery-post-op-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vaginal-cuff-surgery-post-op-peptococcus-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vaginal-hysterectomy-infection-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vancomycin-resistant-enterococcus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vancomycin-resistant-enterococcus-faecium-infection 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vanishing-testis-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/varicella 2026-04-19 weekly 0.8 https://druglandscape.com/disease/varicella-chickenpox- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/varicella-chickenpox-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/varicella-chickenpox-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/varicella-chickenpox-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/varicella-chickenpox-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/varicella-chickenpox-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vascular-headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vaso-occlusive-crisis-in-sickle-cell-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vasomotor-rhinitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vasomotor-symptoms-associated-with-climacteric-disturbance 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vasomotor-symptoms-associated-with-menopausal-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vasomotor-symptoms-associated-with-ovarian-deficiency-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vasomotor-symptoms-due-to-menopause 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vasospastic-prinzmetal-s-variant-angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vasospastic-angina-prinzmetal-s-or-variant-angina- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/veno-occlusive-disease-of-the-liver 2026-04-19 weekly 0.8 https://druglandscape.com/disease/venography-peripheral 2026-04-19 weekly 0.8 https://druglandscape.com/disease/venous-thromboembolic-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/venous-thromboembolic-events 2026-04-19 weekly 0.8 https://druglandscape.com/disease/venous-thrombosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/venous-varices 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ventilator-acquired-pneumonia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ventilator-associated-bacterial-pneumonia-caused-by-acinetobacter-baumannii-calcoaceticus-complex 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ventricular-arrhythmia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ventricular-fibrillation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ventricular-tachycardia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ventricular-premature-beats 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vernal-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vernal-conjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vernal-keratoconjunctivitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/verruca 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vertigo 2026-04-19 weekly 0.8 https://druglandscape.com/disease/visceral-leishmaniasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/visualization-of-the-ureteral-orifices 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-a-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-b6-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-d-dependent-rickets 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-d-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-deficiency-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-e-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-k-deficiency-induced-hypoprothrombinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitiligo 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitrectomy-adjunct-to-enhance-visualization 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitreomacular-traction-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vivax-malaria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vomiting 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vomiting-of-pregnancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/von-hippel-lindau-vhl-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vulvovaginal-candidiasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vulvovaginitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/whim-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/waldenstr-m-macroglobulinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/weight-loss 2026-04-19 weekly 0.8 https://druglandscape.com/disease/west-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/wheezing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/wild-type-transthyretin-cardiac-amyloidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/wilson-s-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/wound 2026-04-19 weekly 0.8 https://druglandscape.com/disease/wound-dressing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/xerostomia-secondary-to-radiation-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/xerostomia-secondary-to-sjogren-s-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/yaws 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zinc-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zollinger-ellison-syndrome 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zoster-shingles- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zoster-shingles-booster 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zoster-shingles-booster-adolescent- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zoster-shingles-booster-adult- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zoster-shingles-booster-immunocompromised- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/zoster-shingles-booster-pregnancy- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abdominal-cramps 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abdominal-discomfort 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abdominal-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abnormal-glucose-metabolism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abrasion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/abrasions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/aches 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acne-rosacea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-anterior-uveitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-bronchospasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/acute-post-surgical-hypoparathyroidism 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-renal-cell-carcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-unresectable-or-metastatic-non-small-cell-lung-cancer-nsclc-harboring-a-neuregulin-1-nrg1-gene-fusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/advanced-unresectable-or-metastatic-pancreatic-adenocarcinoma-harboring-a-neuregulin-1-nrg1-gene-fusion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/angina 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anorectal-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/anxiety 2026-04-19 weekly 0.8 https://druglandscape.com/disease/arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/avoiding-attention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/backache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bacteria-that-potentially-can-cause-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/beta-thalassemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/biliary-tract-cancer-btc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bleeding-in-cardiovascular-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bleeding-in-hepatic-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/blisters 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bloating 2026-04-19 weekly 0.8 https://druglandscape.com/disease/breast-lesions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bronchial-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/bruises 2026-04-19 weekly 0.8 https://druglandscape.com/disease/burning 2026-04-19 weekly 0.8 https://druglandscape.com/disease/burns 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiomyopathy-of-wild-type-or-variant-transthyretin-mediated-amyloidosis-attr-cm- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cardiovascular-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/changes-in-mood 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chapped-or-cracked-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chapped-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-graft-versus-host-disease-cgvhd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/chronic-obstructive-pulmonary-disease-copd- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/classic-congenital-adrenal-hyperplasia-cah- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/clogged-ears 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cold 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cold-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/coldness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/common-pain-or-itching-from-swimmer-s-ear 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-caused-by-citrobacter-freundii 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-caused-by-enterobacter-cloacae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-caused-by-enterococcus-faecalis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-caused-by-enterococcus-faecium 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-caused-by-escherichia-coli 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-caused-by-klebsiella-oxytoca 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-intra-abdominal-infections-caused-by-klebsiella-pneumoniae 2026-04-19 weekly 0.8 https://druglandscape.com/disease/complicated-urinary-tract-infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/congestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/coronary-artery-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/coronary-artery-disease-and-left-ventricular-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/corticosteroid-responsive-dermatoses 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cracked-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/cramping 2026-04-19 weekly 0.8 https://druglandscape.com/disease/decompensated-cirrhosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diabetic-kidney-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diaper-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diaper-rash 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diffuse-large-b-cell-lymphoma-dlbcl-not-otherwise-specified 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diffuse-midline-glioma-harboring-an-h3-k27m-mutation-with-progressive-disease-following-prior-therapy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/discomfort 2026-04-19 weekly 0.8 https://druglandscape.com/disease/diseases-other-than-human-smallpox-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/disrupted-sleep 2026-04-19 weekly 0.8 https://druglandscape.com/disease/distributive-shock 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dizziness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dry-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dryness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/dryness-of-the-eye 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ear-congestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/ear-pain-or-itching-from-other-earaches 2026-04-19 weekly 0.8 https://druglandscape.com/disease/embarrassment 2026-04-19 weekly 0.8 https://druglandscape.com/disease/end-stage-renal-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endocrine-resistant-pik3ca-mutated-hormone-receptor-hr-positive-human-epidermal-growth-factor-receptor-2-her2-negative-locally-advanced-or-metastatic-breast-cancer 2026-04-19 weekly 0.8 https://druglandscape.com/disease/endogenous-hypercortisolemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/epileptic-seizures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/excessive-apologizing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/extensive-stage-small-cell-lung-cancer-es-sclc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/familial-chylomicronemia-syndrome-fcs- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fatigue 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fear-of-strangers 2026-04-19 weekly 0.8 https://druglandscape.com/disease/fissured-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/flatulence-associated-with-constipation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/flu-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/flu-like-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/further-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/generalized-myasthenia-gravis-gmg- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/guilt 2026-04-19 weekly 0.8 https://druglandscape.com/disease/head-discomfort 2026-04-19 weekly 0.8 https://druglandscape.com/disease/headache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-ta-tma- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-a-congenital-factor-viii-deficiency- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-a-congenital-factor-viii-deficiency-with-or-without-fviii-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-b-congenital-factor-ix-deficiency- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hemophilia-b-congenital-factor-ix-deficiency-with-or-without-fix-inhibitors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hepatic-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hereditary-angioedema-hae- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/herpes-zoster-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hiding 2026-04-19 weekly 0.8 https://druglandscape.com/disease/high-grade-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-imbalances 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hormone-imbalances-of-insufficiencies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/human-smallpox-disease 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypercholesterolemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperlipidemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hyperphenylalaninemia-hpa- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/hypogammaglobulinemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inability-to-handle-stress 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infarction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infection-with-mycobacterium-tuberculosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infections 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infections-that-are-proven-or-strongly-suspected-to-be-caused-by-susceptible-bacteria 2026-04-19 weekly 0.8 https://druglandscape.com/disease/infertility 2026-04-19 weekly 0.8 https://druglandscape.com/disease/inflammation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/injection-site-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/insect-bites 2026-04-19 weekly 0.8 https://druglandscape.com/disease/insomnia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/insufficiencies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/iron-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/irregular-menstrual-cycles 2026-04-19 weekly 0.8 https://druglandscape.com/disease/irritability 2026-04-19 weekly 0.8 https://druglandscape.com/disease/irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/itching 2026-04-19 weekly 0.8 https://druglandscape.com/disease/l-methylfolate-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/labored-breathing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lack-of-concentration 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lack-of-confidence 2026-04-19 weekly 0.8 https://druglandscape.com/disease/lack-of-libido 2026-04-19 weekly 0.8 https://druglandscape.com/disease/left-ventricular-dysfunction 2026-04-19 weekly 0.8 https://druglandscape.com/disease/liver-support 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-cscc-lacscc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-nsclc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer-nsclc-with-high-c-met-protein-overexpression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-unresectable-or-metastatic-human-epidermal-growth-factor-receptor-2-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/locally-advanced-unresectable-or-metastatic-human-epidermal-growth-factor-receptor-2-her2-negative-gastric-or-gastroesophageal-junction-adenocarcinoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/low-energy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/low-or-imbalance-immune-system 2026-04-19 weekly 0.8 https://druglandscape.com/disease/low-to-intermediate-1-risk-myelodysplastic-syndromes-mds-with-transfusion-dependent-anemia-requiring-4-or-more-red-blood-cell-units-over-8-weeks-who-have-not-responded-to-or-have-lost-response-to-or-are-ineligible-for-erythropoiesis-stimulating-agents-esa- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/macerated-skin 2026-04-19 weekly 0.8 https://druglandscape.com/disease/maintenance-treatment-of-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/malignancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/menstrual-cramps 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-cutaneous-squamous-cell-carcinoma-mcscc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-neuroendocrine-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/metastatic-or-recurrent-locally-advanced-nasopharyngeal-carcinoma-npc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mild-sunburn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mild-to-moderate-dementia-of-the-alzheimer-s-type 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-burns 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-cuts 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-pain-of-arthritis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-skin-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-skin-irritations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-swelling 2026-04-19 weekly 0.8 https://druglandscape.com/disease/minor-throat-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-acute-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderate-to-severe-atopic-dermatitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/moderately-to-severely-active-ulcerative-colitis-uc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/mood-changes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-cramps 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscle-weakness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/muscular-aches 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myelokathexis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myocardial-function 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myocardial-infarctions 2026-04-19 weekly 0.8 https://druglandscape.com/disease/myocardial-ischemia 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nausea 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nerve-pain 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nervousness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/newly-diagnosed-cd33-positive-acute-myeloid-leukemia-aml- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nighttime-cramps-in-calves 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nighttime-cramps-in-feet 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nighttime-cramps-in-legs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nighttime-cramps-in-thighs 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nighttime-cramps-in-toes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-cystic-fibrosis-bronchiectasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/non-small-cell-lung-cancer-nsclc-with-high-c-met-protein-overexpression 2026-04-19 weekly 0.8 https://druglandscape.com/disease/nose-congestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/numbness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/occasional-sleeplessness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/other-causes-of-cognitive-decline 2026-04-19 weekly 0.8 https://druglandscape.com/disease/paroxysmal-nocturnal-hemoglobinuria-pnh- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/partial-onset-seizures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/persistent-or-chronic-immune-thrombocytopenia-itp- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/poor-muscle-coordination 2026-04-19 weekly 0.8 https://druglandscape.com/disease/post-operative-inflammation-following-ocular-surgery 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pregnancy-prevention 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pregnancy-related-vitamin-b-12-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pregnancy-related-vitamin-b-9-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/premenstrual-cramps 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prevention-of-pregnancy 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-biliary-cholangitis-pbc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-central-nervous-system-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-hyperoxaluria-type-1 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-immunoglobulin-a-nephropathy-igan- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/primary-neuroendocrine-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/progressing-desmoid-tumors 2026-04-19 weekly 0.8 https://druglandscape.com/disease/prostate-cancer-with-suspected-metastasis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-arterial-hypertension-pah-group-1-pulmonary-hypertension- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/pulmonary-arterial-hypertension-pah-who-group-1-pulmonary-hypertension- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rash 2026-04-19 weekly 0.8 https://druglandscape.com/disease/rashes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/recurrent-unresectable-or-metastatic-npc 2026-04-19 weekly 0.8 https://druglandscape.com/disease/redness-of-the-eye-due-to-minor-eye-irritations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-r-r-follicular-lymphoma-fl- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-r-r-large-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-cd33-positive-aml 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-acute-leukemia-with-a-lysine-methyltransferase-2a-gene-kmt2a-translocation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-acute-myeloid-leukemia-aml-with-a-susceptible-nucleophosmin-1-npm1-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-follicular-lymphoma-fl- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-large-b-cell-lymphoma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-pediatric-low-grade-glioma-lgg-harboring-a-braf-v600-mutation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relapsed-or-refractory-pediatric-low-grade-glioma-lgg-harboring-a-braf-fusion-or-rearrangement 2026-04-19 weekly 0.8 https://druglandscape.com/disease/relief-of-acute-bronchospasm 2026-04-19 weekly 0.8 https://druglandscape.com/disease/runny-nose 2026-04-19 weekly 0.8 https://druglandscape.com/disease/scrapes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/second-degree-burns 2026-04-19 weekly 0.8 https://druglandscape.com/disease/selected-infective-conjunctivitides 2026-04-19 weekly 0.8 https://druglandscape.com/disease/self-consciousness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sepiapterin-responsive-phenylketonuria-pku- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/septic-shock 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-alopecia-areata 2026-04-19 weekly 0.8 https://druglandscape.com/disease/severe-asthma 2026-04-19 weekly 0.8 https://druglandscape.com/disease/shame 2026-04-19 weekly 0.8 https://druglandscape.com/disease/simple-backache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-discomfort 2026-04-19 weekly 0.8 https://druglandscape.com/disease/skin-irritation 2026-04-19 weekly 0.8 https://druglandscape.com/disease/somatostatin-receptor-positive-neuroendocrine-tumors-nets- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sore-mouth 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sore-throat 2026-04-19 weekly 0.8 https://druglandscape.com/disease/soreness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sour-stomach 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sprains 2026-04-19 weekly 0.8 https://druglandscape.com/disease/status-asthmaticus 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stomach-upset 2026-04-19 weekly 0.8 https://druglandscape.com/disease/strains 2026-04-19 weekly 0.8 https://druglandscape.com/disease/stress 2026-04-19 weekly 0.8 https://druglandscape.com/disease/strokes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sunburn 2026-04-19 weekly 0.8 https://druglandscape.com/disease/sunburns 2026-04-19 weekly 0.8 https://druglandscape.com/disease/superficial-punctate-keratitis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/surgery-or-patient-care 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suspected-parkinsonian-syndromes 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suspected-dementia-with-lewy-bodies 2026-04-19 weekly 0.8 https://druglandscape.com/disease/suspected-recurrence-based-on-elevated-serum-prostate-specific-antigen-psa-level 2026-04-19 weekly 0.8 https://druglandscape.com/disease/swollen-glands 2026-04-19 weekly 0.8 https://druglandscape.com/disease/symptomatic-tenosynovial-giant-cell-tumor-tgct-for-which-surgical-resection-will-potentially-cause-worsening-functional-limitation-or-severe-morbidity 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tension 2026-04-19 weekly 0.8 https://druglandscape.com/disease/the-common-cold 2026-04-19 weekly 0.8 https://druglandscape.com/disease/third-degree-burns 2026-04-19 weekly 0.8 https://druglandscape.com/disease/throat-congestion 2026-04-19 weekly 0.8 https://druglandscape.com/disease/thymidine-kinase-2-deficiency-tk2d- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/tingling 2026-04-19 weekly 0.8 https://druglandscape.com/disease/toothache 2026-04-19 weekly 0.8 https://druglandscape.com/disease/treatment-and-prophylaxis-of-hypokalemia-with-or-without-metabolic-alkalosis 2026-04-19 weekly 0.8 https://druglandscape.com/disease/trouble-focusing 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-non-squamous-non-small-cell-lung-cancer-nsclc- 2026-04-19 weekly 0.8 https://druglandscape.com/disease/unresectable-or-metastatic-non-squamous-non-small-cell-lung-cancer-nsclc-whose-tumors-have-her2-erbb2-tyrosine-kinase-domain-activating-mutations 2026-04-19 weekly 0.8 https://druglandscape.com/disease/viral-related-symptoms 2026-04-19 weekly 0.8 https://druglandscape.com/disease/visualization-aid-in-the-cystoscopic-assessment-of-the-integrity-of-the-ureters-in-adults-following-urological-and-gynecological-open-robotic-or-endoscopic-surgical-procedures 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-b-12-cofactor-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/vitamin-b-12-deficiency 2026-04-19 weekly 0.8 https://druglandscape.com/disease/von-willebrand-disorder 2026-04-19 weekly 0.8 https://druglandscape.com/disease/warts 2026-04-19 weekly 0.8 https://druglandscape.com/disease/weakness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/worthlessness 2026-04-19 weekly 0.8 https://druglandscape.com/disease/wound-sepsis 2026-04-19 weekly 0.8